Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2026 Oct 10.
Published in final edited form as: Neuron. 2025 Oct 10;113(24):4178–4198.e9. doi: 10.1016/j.neuron.2025.09.023

Regionally mapped astrocytic responses to cortical and white matter stroke show differential roles in astrocyte-induced vascular remodeling

Amy J Gleichman 1,2,3,4, Riki Kawaguchi 5, Elle M Rathbun 1, Michael V Sofroniew 6, S Thomas Carmichael 1,*
PMCID: PMC12614840  NIHMSID: NIHMS2116475  PMID: 41075786

Summary

Stroke is a major cause of disability. Astrocytes respond to stroke in a gradated manner, but details of that response and its consequences for tissue repair are poorly understood, particularly across brain regions and stroke subtypes. We identified phenotypically and morphologically distinct zones of reactive astrocytes in mouse models of cortical and white matter stroke. Zone-specific transcriptomic analyses revealed that cortical, but not white matter, astrocytes upregulated transcriptional programs promoting the formation of new blood vessels, a key repair mechanism. Viral gain- and loss-of-function strategies showed that astrocytic Lamc1 in particular is an endogenous mechanism by which cortical, but not white matter, astrocytes drive remodeling of larger-caliber brain microvessels. Exogenous induction of Lamc1 in white matter astrocytes improved vessel remodeling and repair and triggered differential T cell infiltration post-stroke. Astrocyte subpopulations show region-specific responses to ischemia that can be leveraged to promote repair, including astrocyte-induced vascular remodeling.

Graphical Abstract

graphic file with name nihms-2116475-f0001.jpg

eTOC blurb:

Gleichman et al. identify and profile zones of reactive astrocytes after two clinically distinct forms of ischemic stroke, revealing similarities and differences. Astrocytes in cortical but not white matter stroke drive vascular remodeling, partially through a Lamc1-dependent mechanism, which can be exogenously induced in white matter astrocytes to increase repair.

Introduction

Astrocytes, one of the most prevalent cell types in the brain1, are highly responsive to neural injury, including stroke. While the details of astrocytic responses to stroke are imperfectly understood, known astrocytic functions both in development and after injury are highly relevant in the post-stroke brain. These functions include synapse formation and elimination2, neural circuit regulation3, vascular4,5 and immune6,7 interactions, and border formation8,9, suggesting astrocytes have high potential to influence post-stroke repair.

Astrocytic reactivity in response to injury is gradated10: adjacent to the injury, astrocytes rapidly exhibit extreme morphologic changes, upregulate the classical astrocyte marker glial fibrillary acidic protein (GFAP), and undergo proliferation, forming an astrocytic barrier around the injury. These changes decline with distance from the injury border11,12, demonstrating heterogeneity in injury-induced astrocytic responses. In addition to reactivity-induced heterogeneity, astrocytes also show intrinsic heterogeneity in the uninjured brain13, most obviously between gray matter, or protoplasmic, astrocytes and white matter, or fibrous, astrocytes14. Astrocyte heterogeneity after injury thus may be a multi-layered phenomenon, encompassing the underlying intrinsic heterogeneity of different regional astrocytic subpopulations and the ways in which those distinct subpopulations respond to injury, as well as how astrocytic responses change with distance from the injury site.

These layers of heterogeneity are of particular relevance in stroke. Ischemic stroke includes both large vessel occlusions15 and blockage of small vessels leading to lacunar infarcts16. Large vessel occlusions include occlusions of the middle cerebral artery (MCA), the most common stroke site17, which reliably show cortical involvement18 and induce well-known stroke symptoms including unilateral flaccidity19. Lacunar infarcts are commonly found in white matter tracts20, and are a key component of cerebral small vessel disease, the underlying pathophysiology of vascular dementia21. Thus, different ischemic insults in the brain, which can be modeled in mice22,23, have distinct regional involvement and clinical correlates.

Tissue remodeling after stroke is a dynamic process, with different temporal windows associated with different processes. Here, we explored spatial and regional changes in astrocyte biology at seven days post-stroke, a sub-acute timepoint during which tissue remodeling is actively underway but not finalized. An analogous subacute phase in patients (<3 months post-stroke) includes high endogenous plasticity that may be boosted by interventions24. The remodeling processes underway at 7 days post-stroke in mouse models includes formation of the astrocytic border around the infarct25; proliferation of astrocytes9,11,25, microglia11, and pericytes26; angiogenesis27; axonal sprouting28; neurogenesis29; and inflammatory responses30, making this a promising timepoint for assessment and manipulation of multiple post-stroke responses to enhance regeneration.

Here, we defined zones of astrocyte reactivity in both cortical and white matter stroke models using phenotypic and morphologic analyses, and used these zones to inform transcriptomic analyses. Leveraging multiple bioinformatic approaches, we identified both shared and divergent roles of post-stroke astrocytes. Using viral loss- and gain-of-function experiments, we identified astrocytic Lamc1 as a pro-angiogenic gene that was endogenously active in cortical, but not white matter, astrocytes, and could be exogenously induced in white matter astrocytes to promote repair.

Results

Phenotypic assessment of post-stroke astrocytic zones

We evaluated astrocyte reactivity in models of cortical stroke (distal middle cerebral artery occlusion, MCAO)31 and white matter stroke (white matter-specific stereotaxic delivery of the vasoconstrictor L-Nio)32 using a panel of markers associated with post-injury reactive astrocytes, including the reactivity marker GFAP (Figure 1A)10. Phosphorylation of extracellular signal regulated kinases 1/2 (pERK) has been associated with increased astrocyte proliferation33 and the induction of reactive astrocytosis after spinal cord injury34. Using colocalization of pERK and astrocyte marker AldoC, we quantified the distance of AldoC+pERK+ astrocytes from the infarct border. In both stroke models, pERK was prevalent almost exclusively in astrocytes in close proximity to the infarct border (Figure 1B, E, G; Table 1).

Figure 1.

Figure 1.

Phenotypic analysis of post-stroke astrocytes.

(A) Cortical and white matter stroke examples. (B) Phosphorylated ERK+ reactive astrocytes in cortical (top) and white matter (bottom) stroke. (C) Individual labeled astrocytes, discrete markers. (D) Reactivity markers analyzed by ratiometric change; Kir4.1 yellow boxes (i) and (ii) expanded, right. Others, ipsilesional (top) vs contralesional (bottom). (E, G) Distribution of discrete count reactivity markers in cortical (E) and white matter (G) stroke. Numbers reflect percentage of cells positive for each marker that are found in each bin. (F, H) Relative change in expression of ratiometric reactivity markers vs contralesional in cortical (F) and white matter (H) stroke, normalized to sham. For (E)-(H) n=5 mice/group, 3 sections/mouse; dashed orange lines: approximate zone boundaries. ****p<0.0001; ***p<0.001; **p<0.01; *p<0.05; two-way ANOVA, Sidak’s multiple comparisons test. Data represent mean ± SEM. Scale bars: (A) 1000μm; (B) left, 150μm; right, 20μm; (C) 10μm; (D) left, 150μm; others, 20μm. See also Figures S1, S2; Table 1.

Table 1:

Characteristics of astrocytic zones, phenotypic markers

Region Marker 0–100μm 100–300μm 300μm–1000μm 1000μm–1500μm Contralat
Cortex EdU+ astrocytes 25.804% ± 2.311 49.37% ± 2.571 24.553% ± 0.719 0.271% ± 0.042 N/A
Ki67+ astrocytes 48.844% ± 5.386 40.767% ± 3.538 8.523% ± 0.762 1.662% ± 0.268 N/A
Lcn2+ astrocytes 39.794% ± 4.379 55.243% ± 2.509 4.962% ± 0.518 0 N/A
pERK+ astrocytes 40.265% ± 4.446 47.269% ± 1.788 12.006% ± 0.657 0.460% ± 0.088 N/A
GFAP intensity **** **** *** ns N/A
GFAP distribution **** **** *** * N/A
Kir4.1 intensity ns **** *** * to ns N/A
Kir4.1 distribution **** ns ns ns N/A
AQP4 distribution ns ** * to ns ns N/A
0–100μm 100–300μm 300μm-midline Above contralat ventricle Lateral to contralat ventricle
White matter EdU+ astrocytes 72.434% ± 3.185 15.151% ± 1.139 7.912% ± 0.481 1.521% ± 0.160 0.054% ± 0.054
Ki67+ astrocytes 71.515% ± 3.264 15.133% ± 1.587 4.756% ± 0.380 8.596% ± 1.463 0
Lcn2+ astrocytes 60.684% ± 4.745 33.524% ± 2.645 5.792% ± 0.310 0 0
pERK+ astrocytes 49.687% ± 2.663 22.019% ± 0.686 18.033% ± 0.355 8.380% ± 2.069 1.692% ± 0.440
GFAP intensity **** **** **** to ** N/A ns
GFAP distribution *** **** **** to *** N/A ns
Kir4.1 intensity **** **** **** to * N/A * to ns
Kir4.1 distribution *** ** to ns ns N/A ns
AQP4 distribution ** **** to *** **** to ns N/A ns
Glt1 intensity * ns ns N/A ns
Glt1 distribution * ns ns N/A ns

Discrete markers: percentage of positive cells per zone. Ratiometric markers, intensity and distribution measurements: (stroke ipsilesional field/contralateral average field) vs (sham ipsilateral field/sham contralateral average field). Two-way ANOVA, Sidak’s multiple comparisons test; displayed, range of significance in 100μm bins within the zone.

****

p<0.0001;

***

p<0.001;

**

p<0.01;

*

p<0.05;

ns = not significant; N/A = not analyzed or used as section-matched control. Data represent mean ± SEM, n = 5 animals, 3 sections/animal.

Astrocytic proliferation varies over the first week post-stroke11,25 and has not been systematically characterized, particularly in white matter. Therefore, we labeled all astrocytes that proliferated after stroke by administering the thymidine analogue EdU for the duration of the post-stroke period, colocalized with astrocyte marker Aldh1l1 (EdU+Aldh1l1+ cells, Figures 1C, S1A, S2A; Table 1). We also identified actively proliferating astrocytes using the mitotic marker Ki67 (Ki67+AldoC+ cells, Figures 1C, E, G; S1B, S2B; Table 1). There were significantly more EdU+ astrocytes at 7 days post-stroke than Ki67+ astrocytes (Figures S1D, S2D), as the peak of astrocyte proliferation occurs before 7 days post-stroke11,25. Distribution patterns around the infarct were similar between EdU+ and Ki67+ astrocytes within each stroke model (Figure 1E, G), suggesting that the spatial distribution of astrocyte proliferation at 7 days post-stroke is broadly unchanged from the cumulative distribution of proliferation over that time. Lipocalin-2 (Lcn2), previously shown to be highly upregulated in MCAO astrocytes35 and implicated in post-stroke inflammation36, was upregulated in both models, with distribution patterns similar to, although sparser than, proliferating astrocytes (Figures 1C, E, G; Figures S1C, S2C; Table 1).

Markers such as GFAP show relative changes in expression, which we assessed with a ratiometric quantification in 100μm increments, incorporating both changes in intensity and distribution of signal (skewness; see Methods). A more even signal distribution in stroke vs sham leads to decreased skewness, whereas more tightly clustered signal leads to increased skewness. GFAP showed dramatic increases in intensity, particularly in cortical stroke with low baseline GFAP. GFAP also showed extreme decreases in skewness, reflecting signal that is much more evenly distributed throughout the field due to upregulation of GFAP in many astrocytes, as opposed to sparse, clustered signal in few cells. These changes persisted for long distances from the infarct border in both stroke models (Figure 1D, F, H; S1E, S2E; Table 1).

We also evaluated expression patterns of Kir4.1, AQP4, and Glt1. Kir4.1, an inwardly rectifying potassium channel predominantly expressed in astrocytes, shows altered expression and polarization in models of stroke, global ischemia, and spinal cord injury37–39, with potential physiologically relevant consequences for potassium homeostasis. Kir4.1 intensity increased in both stroke models, persisting for long distances. Immediately adjacent to the infarct, this was also accompanied by changes in skewness; interestingly, skewness increased after cortical stroke but decreased after white matter stroke, reflecting more clustered Kir4.1 staining in the cortex and more dispersed staining in white matter (Figures 1D, F, H; S2G; Table 1). Similarly, AQP4, a water channel localized primarily to astrocytic endfeet in the healthy brain, decreases in a spatially-selective manner in stroke models40, with disrupted localization in traumatic brain injury models41. AQP4 localization, but not intensity, changed in both stroke models, with a decrease in skewness reflecting a decrease in the polarized perivascular endfoot localization of AQP4 (Figures 1D, F, H; S1F, S2F; Table 1). Decreased expression of the astrocytic glutamate transporter Glt1 has been seen in models of stroke42 and spinal cord injury37. In white matter stroke, Glt1 expression decreased and skewness increased within the first 100μm of the infarct border, reflecting lower, but more clustered, expression patterns (Figure 1F, H; S2H; Table 1); we did not observe consistent changes in Glt1 after cortical stroke.

Compiling these results, we identified three to four putative perilesional zones in white matter and cortical stroke, respectively (Table 1; Figure 1E–H, orange labels). Ipsilesional zones 1–3 were similar between models: 1) the first 100μm from the infarct border; 2) 100–300μm from the border; 3) 300μm to 1000μm (cortical stroke) or the midline (white matter stroke). In cortical stroke, we included one additional ipsilesional zone: 4) 1000μm – 1500μm, in which GFAP skewness remained altered. Given that stroke-induced changes in astrocytes in contralateral cortex have previously been reported43, we also included matched contralesional cortex as zone 5. In white matter stroke, we included two contralesional zones: 4) above the ventricle, matched to the stroke location; 5) lateral to the ventricle. Within white matter, with all markers we found similar responses on either side of the infarct and therefore grouped medial and lateral results up to 300μm laterally.

To assess whether the method of stroke induction (cortical MCAO vs L-Nio-induced white matter vasoconstriction) affected the regional patterns of astrocyte reactivity, we generated a new cortical stroke model using L-Nio-induced vasoconstriction and assessed astrocyte phenotypic changes (Figure S3A). These changes closely mimicked those observed in MCAO astrocytes rather than white matter, suggesting that brain region rather than method of stroke induction is the more critical variable. These patterns of astrocytic reactivity were particularly conserved within the first 300μm from the infarct border in both cortical models, although changes in GFAP and Kir4.1 intensity and skewness did not persist past 600μm from the infarct border in L-Nio-induced cortical stroke. Region-specific features observed in both cortical models included increased Kir4.1 skewness near the infarct border and delayed increases in Kir4.1 intensity, delayed decrease in AQP4 skewness, and more even distribution of proliferated astrocytes as well as pERK+ and Lcn2+ across the first 200μm from the infarct border (Figure S3B–F).

Morphologic assessment of post-stroke astrocytic zones

The most extreme changes in post-stroke astrocytes occur close to the infarct border. To more precisely define the borders of those infarct-adjacent zones, we conducted a morphologic analysis of post-stroke astrocytes in both stroke models using lentiviral membrane-targeted spaghetti monster44 reporters. We optically isolated single transduced astrocytes at varying distances from the infarct border in both models and quantified the number and diameter of astrocytic processes. We also conducted a Sholl analysis to assess overall size and complexity (Figure 2). In both models, astrocytes underwent dramatic remodeling immediately adjacent to the infarct; these changes decreased with distance. Restricting the Sholl analysis solely to astrocytes immediately adjacent to the infarct border, the longest processes of cortical astrocytes were an average of 39.38μm, while the longest processes of white matter astrocytes averaged 61.56μm (Figure 2B). We used these distances as an approximate guide to bin the most reactive astrocytes, rounding up for practicality of implementation of later laser capture experiments: astrocytes with a soma within the first 50μm (cortical) or 100μm (white matter) of the infarct border. Therefore, zone 1 of cortical stroke was refined from its phenotypic definition (Table 1) to a final definition of 0–50μm from the infarct border; white matter zone 1 was not altered.

Figure 2.

Figure 2.

Morphologic analysis of individual post-stroke astrocytes.

(A) Optically isolated single astrocyte examples at different locations from infarct border in cortical and white matter stroke. Scale bars: 10μm. (B) Sholl analysis, infarct border astrocytes, cortical vs white matter stroke; n=13–18 cells, **p=0.0011 (two-tailed unpaired Student’s t test). (C) Mean process diameter of cortical (left) and white matter (right) astrocytes by distance from infarct border. Line: one-phase decay; fit: cortex, r2=0.5176; white matter, r2=0.2876. (D-E) Sholl analysis of cortical (D) and white matter (E) astrocytes after stroke binned by zone. Area under the curve: cortex, zone 1 ****p<0.0001, zone 2 p=0.0564; white matter, zone 1 **p=0.0031. Mean diameter of processes: cortex, zone 1 ****p<0.0001, zone 2 *p=0.0127; white matter, zone 1 ***p=0.001. Number of branch points: cortex, zone 1 ****p<0.0001; white matter, zone 1 *p=0.0124. All vs region-specific sham, one-way ANOVA, Dunnett’s multiple comparisons. Data represent mean ± SEM. Cortex: n=15–22 cells/zone. White matter: n=15–25 cells/zone.

We then assessed morphologic changes within the phenotypically-derived zones to evaluate whether these phenotypic differences also reflected changes in astrocyte morphology. Outside the first 100μm, we found no stroke-induced changes in white matter astrocyte morphology (Figure 2E). In contrast, cortical astrocytes showed a more gradual return to normal morphology, with persistent differences to 300μm in both process diameter and branch point number (Zone 2, Figure 2A, C–D). Together, these analyses refined our definition of zone 1 cortical astrocytes to 50μm from the infarct border and showed clear spatial restriction of overt stroke-induced astrocyte morphological change.

Transcriptomic assessment of post-stroke astrocytic zones

To better understand the changes that occur in distinct post-stroke astrocytic zones, we combined laser capture microdissection with tagged astrocytic ribosomes, enabling immunoprecipitation of astrocytic ribosomes/associated mRNA followed by zone-specific, astrocyte-enriched, ribosome-associated mRNA sequencing. mGFAP-Cre/RiboTag45 mice were generated, in which Cre-dependent HA-tagged ribosomal subunits are expressed preferentially in astrocytes. Using the 77.6 mGFAP-Cre46 mouse line, we found >94% astrocyte specificity in the regions of interest (Figure 3A); areas of higher neuronal contamination (cingulate cortex, secondary somatosensory cortex) were avoided during laser capture. Thus, the final zone definition used for laser capture in cortical stroke was: 1) 0–50μm from the infarct border; 2) 50 to 300μm; 3) 300μm to 1000μm; 4) 1000μm to cingulate cortex; 5) matched contralateral cortex. Final zone definition in white matter stroke: 1) 0–100μm from the infarct border; 2) 100 to 300μm; 3) 300μm to midline; 4) contralateral white matter above ventricle; 5) contralateral white matter lateral to ventricle. Zones and matched sham regions were microdissected using combined light/fluorescent microscopy (Figure 3B, S4A, S4B).

Figure 3.

Figure 3.

Transcriptomic analysis of zones of post-stroke astrocytes.

(A) Astrocyte specificity of HA-labeled ribosomes, mGFAP-Cre/RiboTag mice. n=4 mice/region, 2 sections/mouse. Scale bars, 20μm. Data represent mean ± SEM. (B) White matter infarct identification via autofluorescence and laser capture of zone 1. (C) Enrichment of astrocytic transcripts, de-enrichment of transcripts from other cell types in immunoprecipitated samples. (D) Differentially expressed genes per zone in each stroke model vs region-specific sham, FDR <0.1. (E) Number of and overlap in significantly enriched gene sets (GSEA) in zones 1 and 2 of white matter and cortical stroke. (F) Top 20 gene sets: highest normalized enrichment score in zone 1 or 2 of either stroke model. See also Figure S4, Table S1–3.

To evaluate the extent of astrocyte enrichment in laser microdissected, immunoprecipitated samples, input (total mRNA) and immunoprecipitated (IP; astrocyte-enriched, ribosomally loaded) mRNA from microdissected uninjured cortex and white matter were sequenced, along with microdissected stroke samples encompassing zones 1–3. We compared IP vs input expression and observed moderate enrichment of astrocytic markers and variable levels of de-enrichment of canonical markers from other cell types, including neurons, oligodendrocytes, microglia, and endothelial cells (Figure 3C), suggesting that the processing-heavy pipeline of laser capture microdissection for specific astrocyte zones does allow for cell-type-enriched ribosomal immunoprecipitation, albeit to a lesser extent than found with less tissue processing47.

Within each stroke model the top differentially expressed genes (DEGs) largely clustered by zone, with more robust zonal clustering among the cortical zones (Figure S4C, S4D), reinforcing the concept of biological differences between zones. As expected, most DEGs were found in zone 1, with decreasing numbers in subsequent zones (Figure 3D, Table S1, S2); somewhat surprisingly, we identified very few DEGs past zone 2 (300μm from the infarct border) in either model. We identified more DEGs in zone 1 of cortex vs white matter, possibly reflecting higher variability in the small white matter samples.

To identify potential functional consequences common to the more reactive zones, we turned to Gene Set Enrichment Analysis (GSEA)48. GSEA relies on change in expression of genes within the set of all expressed genes, rather than the exact expression level of any one gene, and compares this profile with gene sets with known biological significance. We focused on zones 1–2 in both models, in which we observed more DEGs. There was extensive overlap in these zones (Figure 3E), suggesting numerous shared astrocytic mechanisms between models that encompass astrocytes within the first 300μm from the infarct. These gene sets heavily reflected immune activation and inflammatory responses, including the most highly enriched gene sets (Figure 3F; Table S3). Other common enriched gene sets included the gene ontology (GO) sets “Response to ischemia” and “Glial cell activation,” reinforcing the validity of the analysis, as well as “ERK1 and ERK2 cascade,” underscoring the immunohistochemical findings of robustly increased pERK staining in these zones.

While we found few genes past zone 2 that passed criteria for differential expression, we observed numerous genes that showed a gradient of expression levels from zones 1 to 5. Therefore, we used Weighted Gene Coexpression Network Analysis49 (WGCNA) to identify modules of genes with similar expression patterns from all IP astrocyte-enriched samples. We were particularly interested in gene modules that correlated with the extent of reactivity and found several modules that significantly correlated with either reactivity across both models or with reactivity in only one stroke model (Figure 4A, B). The magenta module in particular was highly correlated with the level of reactivity in both stroke models, suggesting that the genes in this module may reflect core reactivity genes induced in ischemic astrocytes (Figure 4A–C; Table S4).

Figure 4.

Figure 4.

WGCNA identifies a common module associated with reactivity in both cortical and white matter stroke.

(A) Immunoprecipitated zone-specific WGCNA with gene significance measures for reactivity in either stroke model (Reactivity), cortical stroke (Reactivity, ctx), or white matter stroke (Reactivity, wm), coded by zone. (B) Module-reactivity relationships for all, cortical, or white matter reactivity. Number per cell: Pearson correlation, module eigengene with zone reactivity level. Yellow box: statistically significant correlations (p<0.05, with Bonferroni correction). (C) Magenta module gene expression: log2 fold change vs sham across all zones (reactivity gene significance p<0.05). (D) Top 15 enriched gene ontology categories (biological processes) in magenta module genes. (E) Trem2 upregulation in Aldh1l1+ astrocytes after cortical stroke. Dotted yellow line, infarct border; solid yellow box, higher magnification below. Scale bar, top: 30μm; bottom, 10μm. See also Figure S5, Table S4–6.

To understand the biological relevance of the magenta module, we conducted a GO biological processes enrichment analysis50. We again found strong evidence of high levels of immune activation (Figure 4D). This module also showed enrichment of multiple GO terms related to phagocytosis, regulation of endopeptidase activity, and cell-cell adhesion, suggesting these cells may play multiple roles in restructuring the post-stroke environment (Table S5).

This astrocyte activation module included well-established reactivity-associated genes such as GFAP, Vimentin, and Serpina3n35; somewhat unexpectedly, it also included genes typically found in other cell types. To explore whether this expression reflected contamination from other cell types in IP samples vs upregulation of these genes in astrocytes after stroke, we identified several module genes typically found in other cells51 (Trem2, microglia; B2m, OPCs/endothelial cells/microglia; Ifitm3, endothelial cells/microglia) and evaluated their expression in post-stroke astrocytes by immunohistochemistry or in situ hybridization (ISH). While the majority of the Trem2 immunohistochemical signal colocalized with the microglial/macrophage marker Iba1, there were Trem2+ Iba1− cells, particularly near the infarct border, that colocalized with astrocytic marker Aldh1l1 (Figure 5E); these results confirm recent studies which observed astrocytic expression of Trem2 at 3 days, but not 4 hours, after cortical stroke52 and for prolonged periods after spinal cord injury9. Similarly, a subset of the ISH signal for B2m (Figure S5A) and Ifitm3 (Figure S5B) colocalized with astrocytic marker Slc1a3+, particularly near the infarct border, suggesting that less-traditionally astrocytic genes in the magenta module can reflect ischemia-induced astrocyte reactivity.

Figure 5.

Figure 5.

Differential roles of cortical and white matter astrocytes in post-stroke vasculature development.

(A) Predicted functions of zone 1 cortical vs white matter astrocytes via Ingenuity Pathway Analysis (FDR<0.05), by largest difference in activation z-score. (B) Endothelial proliferation (CD31+EdU+), cortical vs white matter stroke. Cortex vs white matter, zone 1: ***p=0.0001; zone 2: *p=0.0471. Two-way ANOVA, Sidak’s multiple comparisons test, n = 5 animals/model, 3 sections/mouse. (C) Lamc1 expression in cortical and white matter, zone 1 vs sham. Lamc1 zone 1 cortex vs sham, ***FDR = 0.000514904; n = 4 animals/group. (D) Lamc1 (white) in zone 1 cortical astrocytes (Slc1a3, green), ISH. (E) Schematic representation of astrocyte-specific AAV CRISPR vectors and experimental timeline for (F-I). (F) Stroke-induced Lamc1 (white) in astrocytes (Slc1a3, green) transduced with Cas12b (red) and negative control (top) vs Lamc1 gDNA (bottom). (G) CD31+EdU+ cells, control vs Lamc1 gDNA virus. Control vs Lamc1 KO: all vessels, **p=0.0090; vessels > 10μm, *p=0.0148; one-way ANOVA, Sidak’s multiple comparisons test, n = 9–10 animals/group, 3 sections/mouse. (H-I) Infarct border after cortical stroke with negative control (H) vs Lamc1 gDNA (I); yellow box, area of higher magnification (right) showing EdU+ (white) CD31+ (red) colocalization. Scale bars: (D, F) 5μm; (H-I) left: 100μm; right, 30μm. Data represent mean ± SEM. See also Figures S6–S10, Table S7–8.

We were curious if this magenta module was similarly regulated in reactive astrocytes in other conditions. Using the reactivity gene significance score (GS.reactivity), a measure of the correlation between gene expression and the level of reactivity as defined by zone, we correlated GS.reactivity with gene expression changes in magenta module genes in other datasets of reactive astrocytes. We found significant magenta module correlations in other conditions of injury or acute inflammation, including spinal cord injury47, cortical stab wound53, acute systemic inflammation induced by lipopolysaccharide (LPS) injection54, and 1 day post-MCAO35 (Figure S5C; Table S6). While we did not find a significant correlation with previously published 7 day post-MCAO gene changes35, these experiments were conducted by pooling astrocytes from the full ipsilesional cortex, which may have diluted the relevant signal.

However, we found far more variability when we compared the magenta module GS.reactivity scores to reactive astrocytes from other conditions, including aging55 and models of Alzheimer’s disease (AD)56 and Huntington’s disease (HD)57. We found positive correlations in late-stage amyloid, but not tau, models of AD; no correlation in aging or the late-stage Q175 model of HD, and a surprising negative correlation with the R6/2 model of HD (Figure S5E, Table S6). These GS.reactivity-based correlations were mimicked in direct correlations of changes in magenta module genes between zone 1 astrocytes in both stroke models and other datasets (Figure S5D, S5F). Together, these results show that while this magenta module is induced in astrocytes in conditions of acute injury and inflammation around areas of overt tissue damage and fibrosis, it is not reliably induced in other reactivity conditions in progressive neurodegeneration, reflecting the heterogeneous nature of astrocyte reactivity58.

Differences in cortical and white matter astrocytic responses to ischemia

In addition to the magenta module, we identified two other modules with a significant correlation with reactivity: light yellow and yellow. The light yellow module was negatively correlated with reactivity, driven by a strong negative correlation in white matter astrocytes, as cortical reactivity was not correlated. Of the 37 genes in this module with a significant GS score for white matter reactivity (Table S4), 23 were unmapped; the remaining 14 were largely downregulated mitochondrial genes, with enriched GO terms suggesting potential deficits in mitochondrial function specific to white matter astrocytes (Table S5). In contrast, the yellow module strikingly showed a positive correlation with cortical reactivity and a negative correlation with white matter reactivity, suggesting ischemia differentially regulates the genes in this module depending on the brain region involved. The enriched GO terms predicted by these genes suggest numerous functions related to neural development (Table S5).

These differences in white matter and cortical astrocytic responses to stroke were particularly intriguing, as patients with white matter injury tend to have worse recovery59. We reasoned that differences in region-specific astrocytic responses may reveal repair mechanisms that cortical astrocytes use to promote recovery that are impaired or not induced in white matter astrocytes, influencing the slower white matter stroke recovery rate. These mechanisms may reflect potential intervention points: an endogenous cortical repair mechanism may be induced exogenously in white matter to promote enhanced white matter repair. To understand the functions that were differentially induced in white matter and cortical astrocytes after stroke while taking into account differentially expressed genes by zone, we turned to Ingenuity Pathway Analysis (IPA). We examined the top diseases and functions that were predicted to be changed based on gene expression changes (FDR <0.1) in zone 1 of both stroke models (Table S7). We were particularly interested in those with the highest difference in their activation z-score between white matter and cortex zone 1 astrocytes: diseases and functions that showed differential activation patterns between the two stroke models. Of the top ten most differentially activated functions, three involved the formation of new blood vessels and were robustly induced in cortical zone 1 astrocytes (Figure 5A; development of vasculature, angiogenesis, cell movement of endothelial cells). These results suggest that while cortical astrocytes are highly pro-angiogenic, as previously reported60, white matter astrocytes are not.

Vascular remodeling and angiogenesis after large strokes, typically cortical, is strongly associated with repair in both patients and animal models61. Conversely, the role of angiogenesis in white matter stroke is still unclear; while angiogenesis near white matter hyperintensities in patients was recently identified62, the impact of that angiogenesis on repair is unknown. To assess the relative level of vessel formation in cortical and white matter stroke models, we administered EdU beginning shortly before stroke and quantified the number of CD31+EdU+ cells. We found far more proliferated vessels per μm3 in the periinfarct of cortical vs white matter stroke; this difference persisted through the first two zones (300μm from the infarct border) (Figure 5B). We also evaluated CD31+EdU+ cells in L-Nio-induced cortical stroke, to assess the impact of stroke model vs brain region on post-stroke endothelial proliferation. The extent and distribution of endothelial proliferation in L-Nio-induced cortical stroke closely mimicked MCAO cortical stroke, suggesting that brain region is the main determinant in the observed differential vascular remodeling (Figure S6A).

Astrocytic endfeet enwrap blood vessels in healthy brain; this function is actively maintained even after stroke63. Given that white matter and cortical astrocytes appear to have differential effects on vessel remodeling, we explored the structural integrity of astrocytic endfeet post-stroke. Using sparse viral labelling, we observed intact endfeet in both models (Figure S7A). Strikingly, this included observations of endfeet even on extremely thin blood vessel processes, as observed in newly growing vessels, in both models (Figure S7B), suggesting that the structural interactions between astrocytes and post-stroke vasculature are similar in both regions.

To identify critical secreted astrocytic genes that may underlie differences in cortical vs white matter vessel remodeling, we returned to the zone 1 DEGs identified by IPA as having a role in the development of vasculature and extracted those associated with the extracellular region by GO (109 genes). As we were interested in genes that might underlie the increase in cortical vessel remodeling relative to white matter, we further narrowed the list to genes positively associated with cortical reactivity vs white matter reactivity by WGCNA reactivity gene significance (Table S8). Of the top 10 genes, we were particularly interested in Lamc1 (Figure 5C; ***FDR vs sham = 0.000514904), which encodes the laminin γ1 chain and helps form the basement membrane along which new blood vessels grow64. Lamc1 upregulation has previously been associated with post-stroke angiogenesis65, and was the only one of the top 10 genes previously found upregulated in cortical astrocytes after stroke35,60 via a FACS-based transcriptomic approach. That two different techniques both identified Lamc1 as an astrocyte-derived pro-angiogenic factor after cortical stroke suggests that it is a robust finding. We further verified that Lamc1 was indeed induced in cortical but not white matter astrocytes after stroke using ISH (Figure 5D, 6B). Lamc1 upregulation was also observed in cortical astrocytes after L-Nio-induced cortical stroke (Figure S6B).

Figure 6.

Figure 6.

Astrocyte-specific Lamc1 upregulation in white matter stroke induces vessel remodeling.

(A) Lamc1 (white) in zone 1 white matter astrocytes (Slc1a3, green), ISH. (B) Schematic representation of astrocyte-specific lentiviral overexpression vectors and experimental timeline for (C-E). (C) Endothelial proliferation with control virus (lck-smMyc, left) or Lamc1 (right). Control vs Lamc1 overexpression, all vessels: *p=0.0349; vessels > 10μm, *p=0.0179. One-way ANOVA, Sidak’s multiple comparisons test. n = 6 animals/group, 3 sections/mouse. (D) Newborn endothelial cells (CD31+, red; EdU+, white) in arterioles (SMA+, blue) and venules (SMA−, blue) in periinfarct white matter after virus; right, proportion of CD31+EdU+ cells in large vessels (>10μm diameter) that are SMA+. Unpaired two-tailed t-test, n = 6 animals/virus, 3 sections/mouse. (E) No extravascular accumulation of i.v. albumin-647 or biocytin-TMR. Two-way ANOVA, Sidak’s multiple comparisons test. n = 5–6 animals/virus, average 2 sections/mouse. Data represent mean ± SEM. Scale bars: (A) 5μm (C) top, 100μm; bottom, 20μm; (D) arteriole, 20μm; venule, 10μm; (E) 50μm. See also Figure S11.

To explore the role of astrocyte-derived Lamc1 in post-stroke angiogenesis after cortical stroke, we designed a dual-AAV system to knock out astrocytic Lamc1 using Cas12b (Figure 5E). We assessed the efficiency of Lamc1 DNA editing in vitro via cleavage assay (Figure S8A, B) and found the highest degree of cleavage with co-expression of two Lamc1 gDNAs (percentage of edited Lamc1 DNA: 40.1%). As cleavage assays can underestimate genome editing efficiency, we also assessed Lamc1 knockout in astrocytes in vivo via ISH and found a 56.36% decrease in astrocytic Lamc1 puncta in the virally transduced area (Figure 5F, S8C). Given that the fold increase in Lamc1 after stroke was relatively mild, albeit highly significant (Figure 5C), we reasoned that this degree of editing may be sufficient to observe a physiological effect of astrocytic Lamc1 on post-stroke vasculature. Lamc1 viral knockout did not affect the minimal endothelial proliferation observed in uninjured cortex (Figure S8D).

We analyzed post-stroke endothelial proliferation (CD31+EdU+ cells) in zones 1 and 2 in animals that received Lamc1 vs negative control gDNA viruses. Astrocyte-specific Lamc1 viral knockout decreased post-stroke vascular proliferation (CD31+EdU+ cells) (Figure 5G). Surprisingly, this decrease was specific to larger-caliber microvessels (>10μm in diameter; arterioles/venules), while angiogenesis of capillaries was unaffected (Figure 5G–I; S9). While we observed CD31+EdU+ cells in vessels of different diameters in both viral conditions (Figure S9B), mapping the vessel diameter of each CD31+EdU+ cell showed a shift in vessel diameter to smaller diameters with astrocytic Lamc1 knockout. This shift was driven primarily by fewer CD31+EdU+ cells in vessels over 10μm (Figure S9C). Lamc1 knockout did not affect the formation of astrocytic endfeet in the periinfarct cortex (Figure S9D).

To determine the type of larger microvessel remodeling that occurred post-stroke, we examined the distribution of newborn CD31+EdU+ cells in vessels with a diameter >10μm surrounded by SMA+ mural cells (arterioles) vs SMA− or SMA-low (venules)66. The majority of CD31+EdU+ cells were found in SMA+ vessels, suggesting the remodeling is primarily in arterioles; this proportion did not differ with Lamc1 knockout (Figure S10A). To determine vessel functionality, we delivered intravenous tetramethylrhodamine biocytin (biocytin-TMR) and Alexa-647-linked albumin (albumin-647) immediately prior to euthanasia and measured extravascular tracer intensity. Biocytin-TMR is a low molecular weight tracer (869 Da) that can cross the blood-brain barrier (BBB) via paracellular leak, while albumin-647 is a larger protein (66 kDA) that can cross the BBB via transcytosis67. We found no evidence of albumin-647 BBB leak with either virus; biocytin-TMR leak was observed, but was not significantly different with Lamc1 knockout (Figure S10B). There was no difference in the extent of albumin perfusion within vessels, suggesting Lamc1 knockout did not change the formation of vessel lumen, nor did the size of the biocytin-heavy infarct core change (Figure S10B). These results confirm that cortical astrocytes promote vessel remodeling after stroke and further suggest that Lamc1 is a key part of the astrocyte-derived vascular remodeling program, particularly for larger microvessels, but does not impact BBB formation.

Astrocyte-specific Lamc1 upregulation in white matter stroke induces vessel formation and improves repair

Given that Lamc1 was upregulated after stroke only in cortical astrocytes but not white matter (Figure 5C, 6A) and that we observed lower levels of CD31+EdU+ cells after white matter stroke (Figure 5B), we wondered whether inducing Lamc1 in white matter astrocytes might increase white matter vascular remodeling post-stroke. To that end, we overexpressed Lamc1 or a reporter protein (smMyc) via lentivirus specifically in white matter astrocytes (Figure 6B). Infarct size was unchanged at 7d post-stroke, suggesting that Lamc1 overexpression did not change lesion formation (Figure S11A.) We observed an increase in newborn endothelial cells (CD31+EdU+ cells) in the area of virus transduction, and as with Lamc1 knockout in the cortex, this change was restricted to vessels >10μm in diameter and did not reflect a change in capillary angiogenesis (Figure 6C). While CD31+EdU+ cells were observed in vessels of varying size with both viruses (Figure S11B), measuring the vessel diameter of each cell showed a dramatic shift toward larger microvessels in Lamc1-overexpressing animals (Figure S11C). Astrocytic endfeet were intact in both conditions, surrounding both capillaries and larger microvessels (Figure S11D–E). Lamc1 overexpression did not change the proportion of angiogenic arterioles versus venules (SMA+ vs SMA− or SMA-low) (Figure 6D). While i.v. biocytin-TMR showed periinfarct extravascular accumulation at 7d post-cortical stroke (Figure S10B), we observed no evidence of BBB leak of biocytin-TMR or albumin-647 at 7d post-white matter stroke with either virus (Figure 6E). We observed no Lamc1-induced change in the size of the biocytin-labeled infarct core (Figure S11F) or the extent of albumin perfusion of the vasculature (Figure S11G), further supporting a lack of Lamc1 involvement in infarct size and suggesting Lamc1 overexpression does not influence the formation of vascular lumen.

White matter is less vascularized than gray matter68, and the impact of vessel formation on repair after white matter stroke is unclear. We therefore evaluated the long-term effects of astrocyte-specific Lamc1 overexpression and the resultant vascular remodeling. The fibrotic core of CNS injuries includes cells that have infiltrated from the blood12 which may change as a result of differences in vasculature, and reduction of the fibrotic core of CNS injury has been associated with improved axon regeneration in multiple injury models69–71. We therefore investigated the effect of chronic Lamc1 overexpression on the fibrotic scar and the area of lost axons. Astrocyte-specific Lamc1 overexpression led to a decrease in the size of both the fibrotic scar (Col1a1+ area) and the denervated region (NF160+ area) at 4 weeks post-stroke (Figure 7A), suggesting that Lamc1 overexpression may be beneficial for white matter stroke repair. Given the lack of change in infarct size at 7d post-stroke (Figure S11A), this change in fibrotic core was not due to altered initial stroke size but rather altered repair processes.

Figure 7.

Figure 7.

Effects of chronic astrocyte-specific Lamc1 upregulation.

(A) Smaller fibrotic scar (Col1a1+, green) and denervated region (NF160+, red) with Lamc1 upregulation. Col1a1+ area, *p=0.0251; NF160− area, *p=0.0430; two-tailed unpaired Student’s t test; n = 5 mice/virus, 3 sections/mouse. (B) Design of troughs and example. (C) Stroke-dependent decrease in affected forelimb use one week post-stroke (control virus); not seen in Lamc1-injected animals (right). Sham + control virus vs stroke + control virus, 1 week, *p = 0.0419. Two-way ANOVA, Dunnett’s multiple comparisons test, n = 10–12 mice/group. (D) T cell (CD3+) and Treg (CD3+Foxp3+) infiltration. Top: CD3/Foxp3/Dapi. Orange dotted line: infarct core; yellow box, expanded below. Two-way ANOVA, Sidak’s multiple comparisons test, n = 12 mice/virus, 3 sections/mouse. CD3+, control vs Lamc1, *p=0.0169; 0–50μm, **p=0.0053. CD3+Foxp3+, control vs Lamc1, **p=0.0055; infarct core, ****p<0.0001; 0–50μm, **p=0.0025. (E) Bcas1+ density in MBP- area. Unpaired two-tailed t test, **p=0.0060, n = 7–8 mice/virus, 3 sections/mouse. (F) Correlation between percentage of Treg cells in T cell population in infarct core and density of Bcas1+ cells in MBP- area: *p=0.0381, r2=0.2907. Data represent mean ± SEM. Scale bars: (A) 50μm; (D) top, 70μm; bottom, 10μm; (E) 50μm. See also Fig S12, File S1, Video S1.

To more directly test the role of Lamc1 on repair after white matter stroke, and because the white matter stroke is induced below motor cortex32, we developed a behavioral task to assess the effects of white matter stroke and Lamc1 overexpression on handedness and fine motor movements. We designed four-sided troughs filled with peanut butter; mice picked up troughs with one or both front paws, then rotated the troughs to eat peanut butter (Figure 7B; Video S1; supplementary file 1). We tested three groups of mice: 1) sham + control virus, 2) stroke + control virus, and 3) stroke + Lamc1 virus. We assessed preference for using the stroke-affected forelimb (picking up troughs) and fine motor movements (trough rotations). We found no evidence of a stroke-induced deficit in trough rotations in any condition (Figure S12A). However, there was a significant decline in using the stroke-affected limb to pick up troughs 1 week post-stroke in stroke + control virus mice, a deficit not found in Lamc1-overexpressing animals (Figure 7C).

The increased expression of Lamc1 and the resultant vascular remodeling in the peri-infarct region could result in a change in immune cell infiltration. Lamc1 expression in kidney carcinomas is linked to increased immune cell infiltration, including T cells72. Given the growing evidence of critical roles for T cells73, and particularly regulatory T (Treg) cells74,75, in post-stroke repair, we examined whether chronic astrocyte-specific Lamc1 overexpression altered infiltration of all T cells (CD3+ cells) and Treg cells specifically (CD3+Foxp3+ cells). Lamc1 overexpression led to an increase in peri-infarct T cells (CD3+), particularly within 50μm of the infarct border (Figure 7D), and a dramatic increase in Treg cells (CD3+Foxp3+ cells) in both the peri-infarct and the infarct core. Lamc1 overexpression increased the proportion of the T cell population comprised of Treg cells in both compartments (Figure S12B).

Treg cells can increase oligodendrocyte differentiation and remyelination76, while a lack of Treg cells can reduce oligodendrocyte regeneration post-stroke74. Thus, Lamc1-induced functional recovery may occur via increased Treg cell infiltration leading to oligodendrocyte differentiation. We evaluated the effect of Lamc1 overexpression on oligodendrocyte differentiation using ISH for Bcas1, a marker of differentiating oligodendrocytes, combined with immunohistochemical staining for myelin (myelin basic protein, MBP) to quantify Bcas1+ cells in the MBP− area. While we did not observe a change in Bcas1+ cells in the MBP+ peri-infarct (Figure S7C), Bcas1+ cells increased in the MBP− area in Lamc1-overexpressing animals, suggesting a possible ongoing drive to induce remyelination. Intriguingly, the proportion of Tregs in the infiltrating T cells in the infarct core was significantly correlated with the number of Bcas1+ cells in the MBP− area, providing further evidence of a relationship between Lamc1-induced Treg cell infiltration and remyelination.

Together, these data suggest that overexpression of Lamc1 in white matter astrocytes after stroke rapidly induced remodeling of larger-caliber microvessels, forming both arterioles and venules with intact blood-brain barrier. Chronic Lamc1 upregulation led to a smaller scar and denervated region and improved behavioral outcome. This improvement may be due to Lamc1-induced increase in regulatory T cell infiltration and oligodendrocyte differentiation.

Discussion

Here, we subdivided the spatially gradated astrocytic response to cortical and white matter stroke into zones of reactivity. Using transcriptomic analyses, we found strong involvement of legion-adjacent astrocytic zones in post-stroke immune responses and identified a module of genes highly correlated with post-stroke reactivity in both models. Conversely, cortical, but not white matter, astrocytes were predicted to induce post-stroke angiogenesis. Using viral manipulation, we demonstrated that astrocyte-derived Lamc1, a key angiogenic gene, is critical for remodeling larger microvessels after cortical stroke. We leveraged this endogenous cortical repair mechanism to induce vascular remodeling in the white matter by virally overexpressing Lamc1 in white matter astrocytes. Astrocyte-specific Lamc1 overexpression induced endothelial proliferation, a smaller fibrotic scar and denervated region, and improved behavioral outcomes, along with increased regulatory T cell infiltration and oligodendrocyte differentiation. These results suggest that astrocyte-derived Lamc1 can induce larger microvessel remodeling after stroke and that this system, endogenously active in cortex, can be exogenously induced in white matter to promote repair. This study reinforces the promise of astrocytes as targets for neural repair and further reflects the context-specific nature of astrocyte reactivity: even with two similar ischemic injuries, key differences in the astrocytic responses led to different vascularization of the spared tissue and point to a promising target for intervention.

The primary stroke models used here, MCA occlusion and NOS inhibition via L-Nio delivery, induce stroke by different mechanisms. MCA occlusion is common in humans, giving this model high clinical relevance22. Small vessel white matter stroke is more challenging to model. While local vasoconstrictor injection allows precise infarct localization, other roles of the drug can complicate result interpretation77. L-Nio inhibits nitric oxide synthase (nNOS/iNOS/eNOS)78. Within the brain, iNOS and eNOS are expressed in endothelial cells, while nNOS is largely found on neuronal somata not present in the white matter51,79, minimizing potential off-target effects. To assess the contribution of brain region vs stroke method, we generated a model of L-Nio-induced cortical stroke. Strikingly, this model recapitulated key findings of MCAO astrocytes, including patterns of marker activation and astrocytic Lamc1 upregulation.

Using laser capture in astrocytic Ribotag animals, we generated astrocyte-enriched, zone-specific transcriptomes of cortical and white matter stroke. Ribosomally-associated mRNA has a higher correlation with protein than whole-cell mRNA80; by lightly fixing the tissue, we sought to minimize contamination from astrocytic responses to cell isolation-induced injury, found in other tissue dissociation methods81. Spatially restricting our analysis to phenotypically-defined zones leveraged the depth obtained with bulk RNA sequencing while still enriching for the most reactive astrocytes. These spatially-defined, astrocyte-enriched Ribotag datasets in both cortical and white matter stroke complement recent datasets in cortical astrocytes using other stroke models with single cell RNAseq and spatial transcriptomics82,83. This study also complements a recent Ribotag analysis of ipsilateral MCAO astrocytes which found dramatic upregulation of inflammatory responses at both 4 hours and 3 days post-stroke52, suggesting astrocytic pro-inflammatory responses span the hyperacute and subacute post-stroke period, although the consequences of inflammation may differ in different periods84.

While GFAP is a widely used marker of reactive astrocytes, reactivity is a far more diverse process than the ubiquity of GFAP upregulation might suggest85. Context-specific astrocyte reactivity reflects activation of distinct combinations of transcriptional regulators58. Astrocyte proliferation correlates with blood-brain barrier rupture86; disease states with an intact blood-brain do not show astrocyte proliferation. Within stroke, the majority of studies on astrocytes have focused on cortical models. Knockout of astrocyte-secreted Chrdl1 led to a reduced motor deficit after cortical stroke but did not impact sensory deficits87, suggesting that astrocytes may act in a circuit-specific fashion. Within models of white matter ischemia, white matter astrocytes can impact oligodendrogenesis88, and white matter astrocytic mitochondria have been proposed as targets for repair89. As we found a gene module (light yellow) that was negatively correlated with white matter reactivity and largely comprised of mitochondrial genes, we find the latter suggestion particularly intriguing. Recent work has found that astrocytes differ between white matter tracts, suggesting that modeling white matter ischemia in different tracts may be an important avenue of future research90.

Multiple gene programs in these datasets present intriguing possibilities for future study. In the remodeling peri-infarct, astrocytes may influence tissue repair through phagocytosis and physical tissue restructuring, a function common to both astrocytes and microglia91,92. Phagocytosis was bioinformatically implicated in multiple ways, including differential levels of increased migration of phagocytes predicted via IPA (Figure 5A). The expression of TREM2 in highly reactive astrocytes (Figure 4E) is particularly thought-provoking in this context, given its strong association with Alzheimer’s disease and potential roles in phagocytosis93.

We pursued Lamc1 due to expression pattern, angiogenic roles, extracellular localization, and previous identification in cortical astrocytes post-stroke. Interestingly, Lamc1 was recently identified as a risk locus for ischemic stroke94, although the effects on vasculature or post-stroke recovery are unclear. The changes we observed in endothelial cell proliferation suggest that astrocytic Lamc1 can affect vascular remodeling after stroke, which may reflect angiogenesis, vessel enlargement, or both.

Lamc1 is part of the basement membrane; the effects of Lamc1 upregulation on the complex basement membrane structure are unknown. Additionally, while we observed astrocytic endfeet surrounding vessels in all conditions, recent advances have enabled proteomics of the endfoot95. Such an approach may reveal more subtle elements of astrocyte-endothelial cell interaction impacted by stroke and Lamc1.

One possible consequence of remodeling larger microvessels is altered immune cell infiltration. Treg cells in particular have been proposed to impact post-stroke repair73–75; the observed Lamc1-dependent increase in Tregs and the correlated increase in oligodendrocyte differentiation, therefore, may be one mechanism by which astrocytic Lamc1 improved tissue outcome and behavioral recovery. Still, other mechanisms may play a role, including other immune mechanisms and tissue plasticity enabled by increased resource availability.

One objective for this study was to identify shared and divergent roles of cortical and white matter astrocytes in stroke repair. Large, predominantly cortical strokes and small focal white matter lesions, while sharing ischemic origins, are very different injuries. Most patients with middle cerebral artery occlusion show substantial recovery96. White matter ischemic lesions and specific white matter strokes differ in mechanism, location, behavioral impairments, recovery profiles and temporal progression97–100. Assessing recovery after a subcortical lacunar infarct is complex; these lesions may not result in overt symptoms, making it difficult to track both onset and recovery101. However, acute white matter strokes tend to have worse outcomes, particularly relative to lesion size59. In longitudinal imaging of patients with symptomatic lacunar infarcts, rather than observing improvement over time, roughly half of patients developed additional white matter abnormalities adjacent to the initial injury102. Given these differences in post-stroke recovery in patients, we undertook to identify astrocytic mechanisms that might underlie differences in post-stroke repair in mouse models. Lamc1-dependent vascular remodeling appears to be one mechanism by which intrinsic differences in astrocytic subpopulations can be leveraged to promote repair.

Resource availability

Lead contact:

Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, S. Thomas Carmichael (scarmichael@mednet.ucla.edu).

Materials availability:

Plasmids generated in this study contain a miR124-T targeting sequence provided by Dr. Gilles Bonvento; this sequence is subject to a Material Transfer Agreement and availability is therefore restricted.

Data and code availability:

RNAseq data generated in this study are available through the Gene Expression Omnibus (GEO) with accession number GSE263986. Accession numbers for publicly available data analyzed for this study are listed in the key resources table. This paper does not report original code. Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request.

Key resource table

REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Rat anti-GFAP Thermo Fisher Scientific Cat #13-0300; RRID: AB_2532994
Rabbit anti-Iba1 FUJIFILM Wako Pure Chemical Corporation Cat# 019-19741, RRID:AB_839504
Goat anti-AldoC Santa Cruz Biotechnology Cat# sc-12066, RRID:AB_2226594
Rabbit anti-phosphoERK Cell Signaling Technology Cat# 4370, RRID:AB_2315112
Rabbit anti-Aldh1l1 Abcam Cat# ab87117, RRID:AB_10712968
Goat anti-Lcn2 R and D Systems Cat# AF1857, RRID:AB_355022
Mouse anti-Ki67 BD Biosciences Cat# 556003, RRID:AB_396287
Rat biotinylated anti-Ki67 Thermo Fisher Scientific Cat# 13-5698-80, RRID:AB_2572793
Rabbit anti-Kir4.1 Alomone Labs Cat# APC-035, RRID:AB_2040120
Rabbit anti-Aqp4 Millipore Cat# AB3594, RRID:AB_91530
Guinea pig anti-Glt1 Frontier Institute Cat# GLT1-GP, RRID:AB_2571720
Rabbit anti-FLAG Thermo Fisher Scientific Cat# PA1-984B, RRID:AB_347227
Chicken anti-V5 Abcam Cat# ab9113, RRID:AB_307022
Human anti-V5 Absolute Antibodies Cat# Ab00136-10.0, RRID:AB_3678832
Goat anti-Myc Abcam Cat# ab19234, RRID:AB_731663
Rat anti-HA Roche Cat# 11867423, RRID:AB_2314621
Sheep anti-Trem2 R and D Systems Cat# AF1729, RRID:AB_354956
Rat anti-CD31 BD Biosciences Cat# 550274, RRID:AB_393571
Rabbit anti-Myc, 488 labeled Biotium Cat# 20436 RRID:AB_3094486
Rabbit anti-Myc, 543 labeled Biotium Cat# 20437, RRID:AB_3095610
Rabbit anti-FLAG, 543 labeled Biotium Cat# 20433, RRID:AB_3095611
Rabbit anti-Col1a1 Abcam Cat# ab21286, RRID:AB_446161
Mouse anti-NF160 Abcam Cat# ab7794, RRID:AB_306083
Chicken anti-GFAP Rockland Cat# 200-901-D60, RRID:AB_11181163
Rabbit anti-CD3 Cell Signaling Cat# 78588, RRID:AB_2889902
Rat anti-Foxp3 Thermo Fisher Scientific Cat# 14-5773-82, RRID:AB_467576
Mouse anti-SMA Millipore Sigma Cat# A5228, RRID:AB_262054
Goat anti-MBP Neuromics Cat# GT22104, RRID:AB_3678833
Bacterial and virus strains
NEB Stable Competent E. coli New England Biolabs Cat #C3040H
Lentivirus, GfaABC1D-lck-smFLAG-miR124T This study N/A
Lentivirus, GfaABC1D-lck-smMyc-miR124T This study N/A
Lentivirus, GfaABC1D-lck-smV5-miR124T This study N/A
Lentivirus, GfaABC1D-Lamc1-FLAG-miR124T This study N/A
AAV, GfaABC1D-BhCas12b-miR124T This study N/A
AAV, U6-negative control gDNA-GfaABC1D-lck-smMyc-miR124T This study N/A
AAV, U6-Lamc1 gDNA 1-Lamc1 gDNA 2-GfaABC1D-lck-smMyc-miR124T This study N/A
AAV, GfaABC1D-lck-smV5-miR124T This study N/A
Chemicals, peptides, and recombinant proteins
2’-Deoxy-5-ethynyluridine (EdU) Biosynth Carbosynth Cat #NE08701
Sulfo-cyanine3 azide Lumiprobe Cat #D1330
Sulfo-cyanine5 azide Lumiprobe Cat #C3330
Mouse-on-mouse block Vector Labs Cat #MKB-2213
HCR probe: Slc1a3, hairpin B3 Molecular Instruments N/A
HCR probe: B2m, hairpin B1 Molecular Instruments N/A
HCR probe: Ifitm3, hairpin B1 Molecular Instruments N/A
HCR probe: Lamc1, hairpin B1 Molecular Instruments N/A
HCR probe: Cas12b, hairpin B4 Molecular Instruments N/A
HCR probe: Bcas1, hairpin B1 Molecular Instruments N/A
Probe hybridization buffer Molecular Instruments N/A
Probe wash buffer Molecular Instruments N/A
Amplification buffer Molecular Instruments N/A
Hairpin B3-488, 1 and 2 Molecular Instruments N/A
Hairpin B1-647, 1 and 2 Molecular Instruments N/A
Hairpin B4-546, 1 and 2 Molecular Instruments N/A
TrueView Autofluorescence Quenching Kit Vector Labs Cat #SP-8400-15
Fluoro-Gel Mounting Medium Electron Microscopy Services Cat# 17985-30
DPX Mounting Medium Electron Microscopy Services Cat #13512
Poly-D-lysine Sigma Aldrich Cat #P6407
DMEM media + GlutaMAX, glucose, and pyruvate Gibco Cat #10569
Heat-inactivated FBS Gibco Cat #16140-071
Polyethylenimine (PEI) Polysciences Cat #23966-1
Caffeine Sigma Aldrich Cat #C0750
Salt-active nuclease ArcticZymes Cat #70910-202
Pluronic F-68 Gibco Cat #24040-032
HiFi DNA Assembly Master Mix New England Biolabs Cat #E2621L
TransIT-X2 Dynamic Delivery System Mirus Bio Cat #MIR 6004
G418 Invivogen Cat #ANTGN1
Biocytin-TMR Thermo Fisher Scientific Cat #T12921
Albumin-647 Thermo Fisher Scientific Cat #A34785
Critical commercial assays
Mix-n-Stain™ Biotin Antibody Labeling Kit Biotium Cat #92266
Lenti-X p24 Rapid Titer Kit Takara Cat # 631476
Alt-R Genome Editing Detection Kit Integrated DNA Technologies Cat #1075932
TruSeq RNA Library Prep Kit with Ribo-Zero Illumina Cat #RS-122-2202
Deposited data
Input and immunoprecipitated RNA-seq, cortical and white matter stroke This study GEO: GSE263986
Spinal cord injury astrocytes Anderson et al.47 GEO: GSE76097
Stab wound astrocytes Sirko et al.53 GEO: GSE66370
Lipopolysaccharide-induced astrocytes Hasel et al.54 GEO: GSE148610
MCAO ipsilesional astrocytes Zamanian et al.35 GEO: GSE35338
Aged motor cortex astrocytes Boisvert et al.55 GEO: GSE99791
Alzheimer’s disease model astrocytes Jiwaji et al.56 European Nucleotide Archive: E-MTAB-10985
Huntington’s disease model astrocytes Diaz Castro et al.57 GEO: GSE124846
Experimental models: Cell lines
HEK-293 ATCC Cat #CRL-3216, RRID:CVCL_0063
SVEC4-10 ATCC Cat #CRL-2181, RRID:CVCL_4393
Experimental models: Organisms/strains
B6.Cg-Tg(Gfap-cre)77.6Mvs/2J Gregorian et al.46 RRID:IMSR_JAX:02 4098
B6N.129-Rpl22tm1.1Psam/J Sanz et al.45 RRID:IMSR_JAX:01 1029
C57BL/6J Jackson Laboratory RRID:IMSR_JAX:00 0664
Oligonucleotides
Cas12b titering primers: Fwd, GCTCTGAAGGCTCTGGAACA; Rev, GATTTCCCGCCAGCCTCTAA This study N/A
hGH titering primers: Fwd, CCTGGGTTCAAGCGATTCT; Rev, CAGCCTGGCCAATATGGT Gleichman et al.31 N/A
Negative control gDNA: GACGCTTCCGAGTACGGTACAGC This study N/A
Lamc1 gDNA 1: CTTATCAGTACTACAGTGGGTCC This study N/A
Lamc1 gDNA 2: ATCAGTACACAAGGCCTGCTGCT This study N/A
Recombinant DNA
Lentivirus backbone: pLenti-MP2 Pantelis Tsoulfas103 Addgene #36097
AAV backbone: AAV-pmSyn1-EBFP-Cre Hongkui Zeng104 Addgene #51507
AAV:ITR-U6-sgRNA(Kras)-U6-sgRNA(p53)-U6-sgRNA(Lkb1)-pEFS-Rluc-2A-Cre-shortPA-KrasG12D_HDRdonor-ITR (AAV-KPL) Feng Zhang105 Addgene #60224
pCAG_smFP FLAG Loren Looger44 Addgene #59756
pCAG_smFP V5 Loren Looger44 Addgene #59758
pCAG_smFP Myc Loren Looger44 Addgene #59757
pZ149-pcDNA3-BhCas12b_v4 Feng Zhang106 Addgene #122446
pLenti CMV GFP Neo (657-2) Eric Campeau and Paul Kaufman107 Addgene #17447
Lamc1 Transomic Technologies Cat #BC165945
Software and algorithms
ImageJ National Institutes of Health RRID:SCR_014210
GraphPad Prism 8 GraphPad Software RRID:SCR_002798
R v4.3.2 R core team RRID:SCR_001905
Nikon NIS Elements Nikon Instruments RRID:SCR_014329
Imaris Bitplane RRID:SCR_007370
STAR 2.4.0 Dobin et al.108 RRID:SCR_004463
HTSeq Putri et al.109 RRID:SCR_005514
Galaxy The Galaxy community110 RRID:SCR_006281

STAR Methods

Experimental model and study participant details

Mice

Animal procedures were performed in accordance with the US National Institutes of Health Animal Protection Guidelines and the University of California Los Angeles Chancellor’s Animal Research Committee, protocol 2000-159. All mice were housed in a facility with 12hr-12hr light-dark cycle, controlled temperature and humidity, and had ad libitum access to food and water. All studies used male mice. Mice underwent surgery at 3–4 months of age. Ribotag experiments: The mGFAP-Cre 77.6 mouse strain was provided by Dr. Michael Sofroniew46 and is available from Jackson Laboratory (strain 024098); this line shows robust and widespread astrocytic recombination111,112. The Ribotag mouse strain45 was obtained through Jackson Laboratory (strain 011029) and were crossed with mGFAP-Cre 77.6 mice to Ribotag homozygosity. All other experiments: C57BL/6J mice were obtained through Jackson Laboratory (strain 000664). Animals were randomized between groups for each experiment.

Cell lines

HEK-293 cells (ATCC #CRL-3216) were used for lentivirus and AAV packaging. SVEC4-10 cells (ATCC #CRL-2181) were used to assess CRISPR Lamc1 DNA editing efficiency in vitro.

Method details

Stroke induction

Mice were anesthetized with isoflurane, placed in a stereotaxic frame (Kopf Instruments), and maintained a body temperature of 37.0°C ± 0.5°C throughout surgery via a homeothermic monitoring system. Middle cerebral artery occlusion (MCAO) was performed by electrocoagulation of a distal branch of the MCA, as described31. The temporal muscle on the left side of the skull was bisected and a craniotomy was performed over the distal MCA branch. The branch point was then electrocoagulated to permanently occlude the MCA, followed by 15min bilateral clamp of the jugular vein. White matter stroke was induced via local injection of vasoconstrictor N5-(1-iminoethyl)-L-ornithine (L-Nio) as described previously32. L-Nio was resuspended in sterile saline at a final concentration of 27mg/ml; 200nl of L-Nio was injected into subcortical white matter at 3 sites along the anterior-posterior axis. Sites: 1) A/P −0.75, M/L 0.96, D/V −2.25; 2) A/P −1.00, M/L 0.96, D/V −2.20; 3) A/P −1.25, M/L 0.96, D/V −2.15. White matter stroke sections were evaluated immediately after sectioning; animals with clear involvement of non-white matter tissue in the lesion were excluded.

Cortical L-Nio-induced stroke was performed via pulled glass capillary pipette injection of two injections of 400nl of L-Nio (27mg/ml in sterile saline) at two depths in the cortex. The pipette was lowered to the first depth and left in place for 2min before the first injection. After the first injection, the pipette was left in situ for 10min, then lowered to the second depth and the injection was repeated. After the second injection, the pipette was left in situ for 5min before withdrawal. Sites: 1) A/P 0, M/L 2.75, D/V −0.3; 2) A/P 0, M/L 2.75, D/V −0.75.

Tissue processing and immunohistochemistry

Animals were perfused with 4% paraformaldehyde (PFA) in phosphate buffered saline (PBS) (most experiments) or periodate-lysine-PFA (PLP; Col1a1 experiments: 2% PFA, 0.01M NaIO4, 0.1M lysine, 0.175M sodium phosphate buffer, pH 7.4). Brains were postfixed for 3–4 hrs (single astrocyte morphological reconstructions) or overnight (all other experiments) in 4% PFA (most experiments) or PLP (Col1a1 experiments), cryoprotected 2–3d in 30% sucrose, and frozen in powdered dry ice. Frozen brains were sectioned on a microtome (American Optical Company, model 860) at 100μm thickness (single astrocyte morphological reconstructions) or on a cryostat (Leica CM3050) at 40μm thickness (all other experiments) and stored in a glycerol-based antifreeze solution at −20°C until immunostaining. Sections were immunostained as previously reported31; briefly, sections were washed in PBS, underwent antigen retrieval in 10mM sodium citrate pH 6 at 80°C for 30min, blocked in 5% normal donkey serum (NDS) and 0.3% TritonX-100 in PBS for 1 hr; in experiments with mouse primary antibodies, block was supplemented with Mouse-On-Mouse block (Vector Labs, #MKB-2213). Sections were incubated with primary antibody (PBS, 2% NDS, 0.3% TritonX-100) at 4°C for 3–5 days (single astrocyte morphological reconstructions) or 1–2 days (all other experiments). In experiments that included EdU detection, sulfo-azide EdU detection was performed between antigen retrieval and block, as previously described32. Sections were then washed in PBS with 0.3% TritonX-100 and incubated with secondary antibody for 3–4 hrs (single astrocyte morphological reconstructions) or 1–2hrs (all other experiments) (1:1000 dilution; PBS, 2% NDS, 0.3% TritonX-100). Sections were washed, mounted on gelatinized slides, cleared with increasing concentrations of ethanol and xylene, and coverslipped with DPX (Electron Microscopy Services, #13512). Primary antibodies used for immunostaining: rat anti-GFAP (Thermo Fisher Scientific, #13-0300, 1:1000), rabbit anti-Iba1 (Wako, #019-19741, 1:500), goat anti-AldoC (Santa Cruz Biotechnology, #sc-12066, 1:100), rabbit anti-phosphoERK (Cell Signaling Technology, #4370, 1:500), rabbit anti-Aldh1l1 (Abcam, #ab87117, 1:400), goat anti-Lcn2 (R&D Systems, #AF1857, 1:500), mouse anti-Ki67 (BD Biosciences, #556003, 1:100), rat biotinylated anti-Ki67 (Thermo Fisher Scientific, #13-5698-80, 1:1000), rabbit anti-Kir4.1 (Alomone Labs, #APC-035, 1:400), rabbit anti-AQP4 (Millipore, #AB3594, 1:200), guinea pig anti-Glt1 (Frontier Institute, #GLT1-GP, 1:200), rabbit anti-FLAG (Thermo Fisher Scientific, #PA1-984B, 1:400), chicken anti-V5 (Abcam, #ab9113, 1:500), human anti-V5 (Absolute Antibody, #Ab00136-10.0, 1:400), goat anti-Myc (Abcam, #ab19234, 1:500), rat anti-HA (Roche, #11867423, 1:100), sheep anti-Trem2 (R&D Systems, #AF1729, 1:100), rat anti-CD31 (BD Biosciences, #550274, 1:100), rabbit anti-Myc 488 labeled (Biotium, #20436, 1:400), rabbit anti-Myc 543 labeled (Biotium, #20437, 1:400), rabbit anti-FLAG 543 labeled (Biotium, #20433, 1:400), rabbit anti-Col1a1 (Abcam, #ab21286, 1:200), mouse anti-NF160 (Abcam, #ab7794, 1:500), chicken anti-GFAP (Rockland, #200-901-D60, 1:500), rabbit anti-CD3 (Cell Signaling, #78588S, 1:500), rat anti-Foxp3 (Thermo Fisher Scientific, 14-5773-82, 1:100), goat anti-MBP (Neuromics, #GT22104, 1:2000), mouse anti-SMA (Millipore Sigma, #A5228, conjugated to biotin; conjugated, 1:200). Anti-SMA biotin conjugation via biotinylation kit (Biotium, #92266) per the manufacturer’s instructions.

Plasmid construction

Lentivirus and adeno-associated virus (AAV) transfer plasmids were generated using Gibson cloning113 as previously described31. Briefly, target inserts were generated by PCR; backbones were generated by restriction digest. Short sequences, including gDNA sequences and FLAG tag to identify exogenous Lamc1, were generated by synthesis or integrated into primers (Integrated DNA Technologies).

Lentiviral vectors (astrocyte morphology, Lamc1 overexpression): We used the minimal GFAP promoter, GfaABC1D, to drive expression in astrocytes, and included a miRNA-124 targeting cassette to minimize off-target expression in neurons and progenitor cells114. To fully elaborate astrocytic morphology, we expressed membrane-targeted spaghetti monster reporters using an N-terminal Lck tag.

Dual AAV vectors for Lamc1 knockout: one virus drove expression of BhCas12b in astrocytes, taking advantage of the GfaABC1D promoter and the miR124T targeting sequence to achieve astrocytic high specificity31,114. The second virus contained either a) a U6 promoter driving expression of a negative control guide DNA (gDNA), or b) two U6 promoters, each driving expression of Lamc1-specific gDNA; these cassettes were followed by an astrocytic spaghetti monster-Myc (smMyc)44 reporter to identify transduced astrocytes.

Backbone plasmids: AAV, AAV-pmSyn1-EBFP-Cre104; AAV pmSyn1-EBFP-Cre was a gift from Hongkui Zeng (Addgene plasmid # 51507; http://n2t.net/addgene:51507; RRID:Addgene_51507). Lentivirus, pLenti-MP2103; pLenti-MP2 was a gift from Pantelis Tsoulfas (Addgene plasmid # 36097; http://n2t.net/addgene:36097; RRID:Addgene_36097). Inserts: pCAG_smFP V5 (Addgene plasmid # 59758; http://n2t.net/addgene:59758; RRID:Addgene_59758), pCAG_smFP FLAG (Addgene plasmid # 59756; http://n2t.net/addgene:59756; RRID:Addgene_59756), and pCAG_smFP Myc (Addgene plasmid # 59757; http://n2t.net/addgene:59757; RRID:Addgene_59757) were gifts from Loren Looger44. BhCas12b_v4106 and U6105: pZ149-pcDNA3-BhCas12b_v4 (Addgene plasmid # 122446; http://n2t.net/addgene:122446; RRID:Addgene_122446) and AAV:ITR-U6-sgRNA(Kras)-U6-sgRNA(p53)-U6-sgRNA(Lkb1)-pEFS-Rluc-2A-Cre-shortPA-KrasG12D_HDRdonor-ITR (AAV-KPL) (Addgene plasmid # 60224; http://n2t.net/addgene:60224; RRID:Addgene_60224) were gifts from Feng Zhang. The open reading frame of Mus musculus Lamc1 was purchased (Transomic Technologies, #BC165945). The negative control gDNA was designed based on a sequence not found in the Mus musculus genome115, with very limited predicted off target sequences (CasOFFinder116). The lck tag was included on reporters to ensure membrane insertion and full astrocytic process labeling117. DNA fragments were enzymatically assembled using HiFi DNA Assembly (New England Biolabs). Sequences were confirmed by Sanger sequencing (Laragen Sequencing and Genotyping) and whole-plasmid sequencing (Primordium Labs). Plasmids were transformed in NEB Stable high efficiency E. coli (New England Biolabs).

Virus preparation and injection

Lentivirus was packaged in HEK293 cells using 3rd generation packaging plasmids. Briefly, HEK293 cells were split at ~50% confluency into 15cm dishes coated with poly-D-lysine (5μg/ml in PBS; coated 1hr RT). Cells were maintained in DMEM media + GlutaMAX, glucose, and pyruvate, and supplemented with heat-inactivated FBS. ~24 hrs after splitting, cells were transiently transfected with PEI118; per 15cm plate, cells received: 27.6μg transfer plasmid, 13.8μg pMDLg/pRRE plasmid, 6.9μg pRSV-REV plasmid, and 6.9μg pMD2.G plasmid. The next day, the media was changed and supplemented with 2mM caffeine. Lentivirus-containing media was collected at 48hr and 72hr post-transfection. Media was centrifuged at 1500 × g for 10min at 4°C, filtered through a 0.45μm SFCA membrane, and stored at 4°C until centrifugation. Lentivirus was concentrated first by centrifugation in a SW 32 Ti rotor (Beckman Coulter) at 20,000 RPM for 2hr 20min at 4°C. The lentiviral pellet was resuspended DPBS and loaded onto a 30% sucrose gradient, then centrifuged in a SW 55 Ti rotor at 32,000 RPM for 2hr 20min at 4°C. The final pellet was resuspended in DPBS, centrifuged at 7K × g for 5min at room temperature, and the supernatant was aliquoted and stored at −80°C. Lentivirus titer was measured with an ELISA-based p24 assay (Lenti-X p24 Rapid Titer Kit) per the manufacturer’s instructions. On the day of injection, aliquots were thawed, centrifuged at 7K × g for 5min at room temperature, and diluted as needed in sterile saline. Virus (single astrocyte morphology and white matter astrocytic endfeet: 1–3 × 10^9 vg/ml; Lamc1 or control overexpression: 1×10^11 vg/ml) was loaded into pulled glass capillary pipettes for injection and stored on ice until use.

Lentiviruses trigger rapid transgene expression after injection and their larger capsid size leads to a smaller transduced area; therefore, the use of lentiviral vectors allowed us to inject virus immediately after stroke, and observe robust expression within several days. Single astrocyte morphology: viruses were injected at different distances from the injury and morphology assessed seven days post-stroke as a function of distance from the infarct border. Lamc1 overexpression: lentiviral constructs expressing FLAG-tagged Lamc1 or a reporter protein (smMyc) were locally delivered to white matter; the relatively small transduction area of lentivirus allowed expression patterns largely restricted to white matter. Single astrocyte morphology, white matter: A/P −0.85, M/L +0.81, D/V −2.3; A/P −1.10, M/L +1.11, D/V −2.17; A/P −1.15, M/L: −0.78, D/V −2.26. Single astrocyte morphology, cortex: 3 ipsilesional and one contralesional sites per mouse between A/P +0.5 to −0.8, M/L ±1.5 to 2.3; all, D/V −0.75. Lentivirus was injected in a range of locations due to the large and variable infarct location of MCAO, to label astrocytes at a range of distances. Lamc1 or control overexpression, white matter: A/P −0.85, M/L +0.81, D/V −2.3; A/P −1.10, M/L +1.11, D/V −2.17. All: 200nl/site.

AAV was packaged in HEK293 cells in the PHP.eB serotype119. Briefly, cells were transiently transfected with PEI, media was collected at 3d post-transfection, and media and cells were collected at 5d post-transfection118. Cells were lysed with salt-activated nuclease incubation. AAV particles were separated on an iodixanol gradient via ultracentrifugation. Iodixanol was removed and viral particles were concentrated via buffer exchange columns using DPBS with 0.001% Pluronic F-6831. AAV titer was measured via RT-PCR using primers to amplify a region of Cas12b or hGH.

Given the longer expression course of AAV, two weeks before stroke, Lamc1 or control knockout viruses were injected intracortically into the area that would encompass peri-infarct cortex to allow time for transgene expression. Diluted virus (2×10^12 vg/ml per each virus in sterile saline) was injected intracortically in 2 sites, two weeks prior to stroke/sham surgery (effects of Lamc1 knockout in stroke) or three weeks prior to euthanasia (effects of Lamc1 knockout in uninjured tissue). To visualize astrocytic endfeet in Lamc1 vs control knockout astrocytes, the injected viral cocktail was supplemented with 2×10^9 vg/ml PHP.eB::GfaABC1D-lck-smV5-miR124T. Injection sites: A/P 0, M/L +2.75, D/V −0.75; A/P −0.8, M/L +2.50, D/V −0.75; 400nl/site. To visualize astrocytic endfeet in cortical stroke vs sham astrocytes, mice were retroorbitally injected with PHP.eB::GfaABC1D-lck-smV5-miR124T (1×10^11 vg/mouse) two weeks prior to stroke/sham surgery.

Laser capture microdissection and ribosomal immunoprecipitation

To prevent mRNA degradation during subsequent laser capture microdissection while minimizing crosslinking that would prevent ribosomal immunoprecipitation, we used brief, minimal fixation followed by immediate sucrose perfusion120. Mice were euthanized via exposure to terminal levels of isofluorane and perfused with PBS for 1min, 0.5% paraformaldehyde for 5min, and 20% sucrose for 5min; rate of 5ml/min. Brains were immediately extracted, frozen in powdered dry ice, and stored at −80C until sectioning. Brains were sectioned on a cryostat, relevant sections were mounted onto PET-membrane slides, and slides were briefly stored in 100% ethanol until laser capture.

Relevant brain areas were sequentially excised in both stroke models, using a combination of light and fluorescent microscopy to identify the autofluorescent infarct core; matched regions in sham-operated animals were also microdissected. Samples immediately collected in supplemented homogenization buffer121 and stored on ice until homogenization. Brain regions in which we observed substantial non-astrocytic HA expression (cingulate cortex; secondary somatosensory cortex) were avoided during the laser capture process; therefore, while morphological analysis of single astrocytes included zone 4 cortical astrocytes to the midline, laser capture ended prior to cingulate cortex. Collected zone samples were further diluted to ~1.5% w/v in additional supplemented homogenization buffer, estimated from the volume of tissue collected.

Samples were homogenized for 30sec using a motorized tissue grinder (Fisher, #12-1413-61). After homogenization, ribosomal immunoprecipitation via HA antibody binding and RNA extraction proceeded as described121.

RNA-sequencing and analysis

RNA-sequencing was carried out using TrueSeq with RiboZero kit (Illumina). Libraries were indexed and sequenced by HiSeq4000 sequencer (Illumina) with 50-bp paired end reads. Quality control (QC) was performed on base qualities and nucleotide composition of sequences, to identify problems in library preparation or sequencing. Reads were aligned to the Mouse reference genome (mm10) using the STAR spliced read aligner (version 2.4.0)108. Read counts were obtained using HT-seq program109 using mouse Ensembl gene model (GRCm38) as reference. Average input read counts were 57.5M per sample and average percentage of uniquely aligned reads was 74.2%. Limma-voom, which is not dependent on negative binomial model, was used for the differential expression analysis122. Four outlier samples were removed based on normalized z-scores greater than 2.0 standard deviations; one sample was removed due to low uniquely aligned read rate (22.6%). Lowly expressed genes were first filtered based on counts per million reads (CPM), Trimmed Mean of M-values (TMM) method was used for normalization, and Empirical Bayes smoothing of standard errors was applied to the linear model. Moderate T-tests were performed for each individual and F-test for multiple comparisons. FDR<0.1 was used to define differentially regulated genes.

Relative enrichment/de-enrichment of samples for genes specific to different cell types was assessed using the log(2) fold change of IP samples versus input samples in uninjured cortex and white matter, as well as pooled zones 1–3 from cortical and white matter stroke to ensure that the level of astrocyte enrichment in IP samples did not change with injury. Zone-specific IP samples were clustered within each brain region (cortex vs white matter) using the top 250 most differentially expressed genes using pheatmap. Significantly enriched gene sets in zones 1 and 2 of each stroke model were assessed using pre-ranked weighted Gene Set Enrichment Analysis48,123. Genes in zones 1 and 2 per model were sorted by (log2FC*-log10 pVal) to incorporate both the magnitude of the change and the statistical significance, and compared to all GO gene sets (v2023.2); overlapping sets were visualized using DeepVenn124. The top gene sets common to all 4 zones were sorted by highest NES in any zone. To aid in visualization of -logFDR, any gene set with an FDR of 0 was increased to 0.00001.

Weighted Gene Correlation Network Analysis was performed on all zone-specific IP samples (zones 1–5 and sham from both models using filtered gene lists within models to exclude lowly expressed genes). Reactivity level was coded 5 (zone 1) to 0 (sham); this was applied to samples from both models (Reactivity) or region-specific models (Reactivity, ctx and Reactivity, wm), in which samples from the non-coded model were designated N/A. Modules were assigned using a signed network with a minimum module size of 30. Module relationships with reactivity were quantified by Pearson correlation of module eigengene and coded reactivity level; significant correlations = p<0.05 with Bonferroni correction. GO enrichment analysis using PANTHER50 (v. 18) was used to assess the potential functional relevance of gene modules (cut-off of p<0.05; Fisher’s exact test.) To assess whether the patterns of magenta module gene changes observed in ischemic stroke astrocytes were common in reactive astrocytes in other conditions, log2 fold change in other datasets was compared to the gene significance of reactivity of each magenta module gene (GS.reactivity, correlation between magenta module gene expression and coded reactivity for both models; p<0.05; 375 genes total). These datapoints for each gene were fit with a linear regression; goodness of fit and whether the slope of the linear regression was significantly non-zero (GraphPad Prism) were used to assess the strength of the relationship between magenta module gene expression in other datasets and ischemic astrocytes. Log2 fold change values for other datasets: spinal cord inury47: downloaded from https://astrocyte.rnaseq.sofroniewlab.neurobio.ucla.edu/. LPS-induced inflammation54: available on GEO (GSE148610). Stab wound injury53 microarray dataset: robust multi-array averages (log2 RMA, stab wound) were downloaded from GEO (GSE66370) and used to generate log2FC. Ipsilesional MCAO35 microarray dataset: counts were downloaded from GEO (GSE35338). Limma-voom via Galaxy (Galaxy tool ID: toolshed.g2.bx.psu.edu/repos/iuc/limma_voom/limma_voom/3.50.1+galaxy0) was used to convert probe IDs to gene name for both microarray studies and calculate log2FC (ipsilesional MCAO). The probe ID with the highest log2FC per gene was used in downstream comparisons. Aged motor cortex55: available in Boisvert et al. supplemental table S2. Alzheimer’s disease, tau and APP/PS1 models56: available in Jiwaji et al. supplementary data 2 and 4. Huntington’s disease, Q175 and R6/2 models57: logCPM values were downloaded from GEO (GSE124846) and used to calculate log2FC.

Ingenuity Pathway Analysis was used to assess differences in predicted diseases and functions associated with zone 1 in both stroke models, using log2 fold change of zone 1 vs sham in each model (cutoff FDR 0.1). Predicted associated diseases/functions were sorted by the largest difference in activation z-score in cortex vs white matter. Genes within the “development of vasculature” function were sorted by associated cellular compartment, using GONet125 to identify genes in the extracellular region. Genes were further sorted by relative association with cortical reactivity vs white matter reactivity by WGCNA reactivity gene significance (GS) (GS.reactivity.ctx – GS.reactivity.wm).

In situ hybridization

In situ hybridization (ISH) was performed using hybridization chain reaction126 (Molecular Instruments). Perfused tissue sections were washed 2x in SSC (0.75M NaCl, 0.075M Na citrate), then pre-hybridized in probe hybridization buffer, 30min 37°C. Sections were then incubated in probe hybridization buffer + probes (0.4pmol mixed probes/100μl hybridization buffer) overnight at 37°C. Sections were washed 4×15min in probe wash buffer, 37°C, followed by 3×5min washes in SSC at room temperature. Hairpin amplifiers were prepared by 90sec heat pulse at 95°C, then allowed to cool to room temperature for 30min, protected from light. Sections were incubated in amplification buffer for 30min at room temperature, followed by overnight incubation in amplification buffer + hairpin amplifiers (6pmol/100μl amplification buffer). Sections were washed in SSC: 1×5min, 2×30min; one 30min wash was supplemented with Dapi. Sections were washed with 1×5min PBS, incubated in TrueView (Vector Labs) to minimize background autofluorescence, washed 1×5min in PBS, mounted on gelatinized slides, and coverslipped with Fluoro-Gel mounting medium (Electron Microscopy Services).

Post-ISH immunostaining

Combined ISH/immunostaining for Bcas1+ cells (ISH) and MBP (immunostaining) was performed sequentially. Sections were processed for ISH as above, mounted, coverslipped, and imaged. Coverslips were then removed and slides were washed 3×5min in PBS before antigen retrieval (10mM sodium citrate, pH 6, 80°C 30min). Slides were washed 3×5min in PBS and blocked in normal donkey serum (5% NDS, 0.3% TritonX-100 in PBS) for 1hr at room temperature. Slides were incubated in primary antibody overnight (anti-MBP, Neuromics goat 1:2000; 0.3% TritonX-100, 2% NDS, in PBS). The next day, slides were washed 3×5min in PBS, incubated in secondary antibody 1–2 hrs, washed 3×5min PBS, and coverslipped.

Vessel leak

Animals were retroorbitally injected 7d post-stroke with a combined solution of biocytin-TMR (Thermo Fisher Scientific, #T12921; 50μl of 1% solution in saline) and albumin-647 (Thermo Fisher Scientific, #A34785, 20μl of 1% solution in saline) and euthanized 30min later. Brains were postfixed for 24hr in 4% PFA, cryoprotected in 30% sucrose for 2 days, frozen in powdered dry ice, and stored at −80°C until sectioning; samples were protected from light throughout processing. Sections were stained for blood vessels and virus (CD31 and Myc/Flag, as above).

Lamc1 CRISPR knockout efficiency analysis

SVEC4-10 cells, which naturally express relatively high levels of Lamc1, were transiently transfected with expression plasmids containing U6-gDNA (negative control, Lamc1 gDNA1, Lamc1 gDNA2, or Lamc1 gDNA 1 & 2), BhCas12b_v4, and CMV-GFP-Neomycin using TransIT-X2 (Mirus Bio). pLenti CMV GFP Neo (657-2) was a gift from Eric Campeau & Paul Kaufman (Addgene plasmid # 17447; http://n2t.net/addgene:17447; RRID:Addgene_17447)107. The day after transfection, media was replaced and supplemented with G418 (500μg/ml, Invivogen); this was repeated every 2–3 days to kill untransfected cells. Seven days post-transfection, cells were lysed and DNA was collected for use in the T7 endonuclease I mismatch cleavage assay, per the manufacturer’s instructions (Alt-R Genome Editing Detection Kit, Integrated DNA Technologies). DNA fragments were separated by agarose gel, imaged, and fragment intensity was quantified using ImageJ.

In vivo editing efficiency: sections from animals that received negative control or Lamc1 gDNA + Cas12b AAVs before cortical stroke underwent ISH for Lamc1, Slc1a3 (astrocytes), and Cas12b. Lamc1 puncta were assessed with Imaris (Bitplane), spots function. Lamc1 spots were then classified by location: within Slc1a3+ surface (astrocytic) vs external to Slc1a3, within the first 300μm from infarct border in the area of Cas12b expression. The proportion of Lamc1 puncta in Slc1a3 surfaces vs total Lamc1 puncta was calculated. gDNA groups were compared using a two-tailed unpaired Student’s t test; n = 6 mice per condition, 2 sections per animal.

Peanut butter trough task

Peanut butter troughs were designed using TinkerCad and printed using resin, 100% infill. Troughs were designed to be 3mm × 3mm × 8mm, for easy directional pick-up by adult mice. Alternating sides were painted with two colors of nail polish to aid identification of turns on video. Five troughs were filled with peanut butter and put in a clear plexiglass arena (15cm × 15cm × 25cm) with the animal for 10 minutes. Animals received 4 training sessions, then were tested before stroke (baseline) and 1, 2, and 3 weeks post-stroke. Animals were food deprived for 8–10 hours prior to training and testing. Animals were recorded from below via mirror to assess trough handling behavior.

Quantification and statistical analysis

Phenotypic and morphologic analysis

To analyze markers with very low or no expression in astrocytes pre-stroke (EdU, Ki67, Lcn2, pERK), we identified positive astrocytes post-stroke and measured their location in relation to the infarct border. The infarct border was identified as the edge of the astrocytic border using one of three astrocytic markers (Aldh1l1/AldoC/GFAP); this border closely mimics the onset of the area of high autofluorescence delineating the infarct core. Markers were colocalized with pan-astrocytic markers Aldh1l1/Aldoc, or GFAP; while GFAP is absent in many healthy gray matter astrocytes, it is robustly and globally upregulated in reactive astrocytes, allowing its use as a pan-astrocytic marker in the peri-infarct cortex. Positive astrocytes from 3–5 sections per animal were combined, binned in 100μm intervals from the infarct border, and the percentage of cells per bin was plotted as a histogram.

To analyze markers with relative change (GFAP, Kir4.1, Glt1, AQP4), a ratiometric analysis was conducted on ipsilesional fields every 100μm from the infarct border. These analyses spanned the dorsal-ventral thickness of white matter or cortex, respectively, including all cortical layers in the latter. We included tissues sections spaced throughout the anterior-posterior axis of the stroke; no overt differences were found along the anterior-posterior axis. We quantified both changes in intensity and distribution of signal. To quantify the latter, we measured the skewness of the field to assess how asymmetrically the signal was distributed throughout the image127. This assessment of signal distribution is complementary to measurements of signal intensity. Mean image intensity and skewness of each field was analyzed using ImageJ. Each field was normalized to five averaged contralesional fields in the same image to account for variation between tissue sections. Contralateral tissue in cortical stroke was designated as the equivalent area of cortex. In the white matter stroke model, the infarct was localized above the ipsilesional ventricle; therefore, we designated the white matter above the contralesional ventricle as the contralesional region. However, given that the white matter is a continuous structure, the relatively short distance between the infarct border and the white matter above the contralesional ventricle, and the proximity of the subgranular zone, we reasoned stroke-induced changes were possible in this area; therefore, we also evaluated changes in the white matter lateral to the contralesional ventricle. Sham ipsilateral tissue was matched to the stroke area. Three sections were averaged per phenotypic marker. All analyses passed normality testing (Kolmogorov-Smirnov, Shapiro-Wilk tests). Stroke vs sham ipsilesional/averaged contralesional fields as a measure of distance from infarct were compared with two-way ANOVAs with Sidak’s multiple comparisons tests.

Single transduced astrocytes were imaged on a confocal microscope (Nikon Instruments C2) at 100x with 0.2μm Z step sizes. Astrocytes were chosen based on the following criteria: no adjacent astrocytes transduced with the same reporter virus; full morphology contained within the section; strong signal-to-noise. The distance from the astrocytic soma to the infarct border was measured. Single astrocytes were optically isolated using Imaris (Bitplane) surfaces module and morphology was reconstructed using filaments module. Mean process diameter and number of branch points in each zone per stroke model passed normality (Shapiro-Wilk testing) and were compared with one-way ANOVAs with Dunnett’s multiple comparisons tests; for Sholl analysis, the area under the curve was computed, then compared with one-way ANOVAs with Dunnett’s multiple comparisons test.

Quantification of newborn blood vessels

Colocalized CD31+ EdU+ cells were analyzed using Imaris image analysis software (Bitplane) with a combination of automated analysis followed by manual curation by a blinded investigator to ensure accurate identification. Positive cells were further quantified based on vessel diameter as large vessels (>10μm) or capillaries (<10μm)128. Cell counts were normalized to the tissue area: region-specific zone, Figure 5B; virally transduced cortex within 300μm of the infarct core (Figure 5G) or white matter (Figure 6D). All experiments: pooled data from 3 sections along the anterior-posterior axis of the stroke per animal. Groups were compared using one-way (viral expression experiments, Figures 5G and 6C) or two-way (stroke model by zone, Figures 5B and S6A) ANOVAs with Sidak’s multiple comparisons tests; all passed normality testing (Shapiro-Wilk test). Vessel identity was analyzed by co-staining for SMA; CD31+EdU+ cells enveloped by SMA+ mural cells were identified as arterioles, while SMA− vessels were identified as venules. The percentage of SMA+ vessels in each viral group passed normality testing and were compared by unpaired two-tailed t-test.

Quantification of vessel diameter per CD31+EdU+ cell

CD31+ EdU+ cell spots on Imaris were split into individual objects and the diameter of the vessel at that spot was analyzed by placing small spots on opposing sides of the vessel. Vessel diameter distribution was analyzed by both cumulative histograms and histograms with 2μm bin sizes. Cumulative histograms of viral groups were compared using nonlinear regression of each dataset via comparison of fits extra sum-of-squares F test (GraphPad Prism).

Quantification of fibrotic scar and denervated region

The fibrotic scar (Col1a1) and axons (NF160) in animals with chronic white matter stroke (4 weeks post-stroke), injected with control or Lamc1 overexpression virus at the time of stroke, were analyzed using ImageJ. The Col1a1+ and NF160− areas were outlined and measured. n = 5 mice per group; averaged 3 sections per animal chosen along anterior-posterior axis. Lamc1 vs control virus groups passed normality testing (Shapiro-Wilk) and were compared using two-tailed unpaired t-tests.

Quantification of T cells

The number and distribution of T cells and regulatory T cells in the white matter 4 weeks post-stroke was analyzed with Imaris. White matter and the infarct core were manually delineated using autofluorescence. Spots on T cells were automatically assigned and manually curated, and further manually subdivided into CD3+Foxp3+ Treg cells. n=12 mice per group; pooled data from 3 sections along the anterior-posterior axis of the stroke per animal. Groups were compared using two-way (Lamc1 vs control virus by distance from the infarct) ANOVAs with Sidak’s multiple comparisons tests.

Quantification of Bcas1+ cells

ISH and immunostained images were aligned in Imaris using Dapi signal from both imaging sessions. Bcas1+ cells in the white matter were manually labeled with spots. The area of low MBP was manually traced and the resulting surface was used for distance transformation to quantify the location of Bcas1+ cells in relation to MBP signal. n = 7–8 mice/virus, combined 3 sections/mouse. Virus groups passed normality testing (Shapiro-Wilk test) and were compared using unpaired two-tailed t test.

Quantification of ISH analysis of Lamc1 in astrocytes in L-Nio-induced cortical stroke

Astrocytic Lamc1+ puncta were quantified using Imaris. Zone 1 (50μm from infarct border) or matched contralateral cortex was manually delineated with a surface. Slc1a3+ territory was automatically identified using surfaces and manually curated. Lamc1+ spots within Slc1a3+ surfaces were automatically identified. Lamc1+ puncta were normalized to Slc1a3 volume in matched contralateral tissue within the same section; density was averaged across two sections per mouse, n=5 mice. Ipsilesional and contralesional Lamc1 density in astrocytic territory passed normality testing (Shapiro-Wilk test) and were compared using paired two-tailed t-test.

Quantification of infarct size, 7d post-stroke

Infarct border was determined by autofluorescence in combination with CD31 and EdU signal and quantified using Imaris surfaces. n=6 animals per virus group; average infarct area per section from 3 sections per animal. Virus groups passed normality testing (Shapiro-Wilk test) and were compared using two-tailed unpaired t-test.

Quantification of vessel leak

Albumin-647 and biocytin-TMR, along with the viral tag (Myc/FLAG) and CD31, were imaged in both ipsilesional and contralesional tissue. Using Imaris, the intravascular signal (CD31) was masked, and the periinfarct tissue was delineated and used to create a surface (cortical stroke, 300μm from infarct border; white matter stroke, area of viral transduction). Remaining mean extravascular signal intensity was normalized to contralateral extravascular signal intensity of the same tissue section in the equivalent region (white matter or cortex). Virus groups within each stroke model were compared using two-way ANOVA, Sidak’s multiple comparisons test. The masked vascular surface was further used to quantify intravascular albumin signal intensity, normalized to contralateral intravascular signal, to assess vessel perfusion. High biocytin levels were observed in the infarct core; the area of this biocytin-heavy core signal was also measured. Virus groups were compared using unpaired t-tests. 5–6 animals per virus, averaged 2 sections per mouse; all groups passed normality testing.

Peanut butter trough behavioral task quantification and analysis

Animals were scored on the first pick-up of each of 5 troughs. Paw preference in picking up troughs was assessed by which paw was first used to grasp the trough: left, right, or both (both paws contacting trough within 2 frames). Degree of preference for the stroke-affected limb (right paw) was scored as two points for use of only the right paw, one point for use of both, and zero points for use of the left paw, normalized to the number of troughs picked up over the testing period (0 to 5). Fine motor movement was assessed by quantifying the number of quarter-turns of the trough the animal completed per pickup on the first pickup per trough divided by the average number of turns completed per trough during baseline testing. n = 12 Lamc1 virus + stroke; 10 control virus + sham; 11 control virus + stroke. Animals were excluded if they picked up fewer than 4 of the 5 troughs over the 10 min session (2 animals in sham condition; 1 in Lamc1 stroke; 2 in control virus stroke) or if the stroke was later found to be off-target (Lamc1, 2 animals; control virus, 3 animals). Stroke groups were compared to sham animals within each time point using two-way ANOVA with Dunnett’s multiple comparisons test.

Supplementary Material

1
2

Supplementary file 1. .stl file for 3D-printed troughs, related to Figure 7 and STAR Methods.

3

Supplementary table 1. Differentially expressed genes in cortical stroke zones, FDR<0.1, related to Figure 3.

4

Supplementary table 2. Differentially expressed genes in white matter stroke zones, FDR<0.1, related to Figure 3.

5

Supplementary table 3. Gene Set Enrichment Analysis, related to Figure 3. Gene Ontology gene sets associated with zones 1 and 2, cortical and white matter stroke models, FDR <0.05. ES: enrichment score. NES: normalized enrichment score. NOM p-val: nominal p-value. FDR q-val: false discovery rate.

6

Supplementary table 4. Weighted Gene Correlation Network Analysis, related to Figure 4. All genes, module membership and reactivity-associated gene significance scores.

7

Supplementary table 5. GO biological processes enriched in the magenta module, related to Figure 4.

8

Supplementary table 6. Correlation of magenta module gene GS.reactivity scores with magenta module gene expression levels in other reactive astrocyte transcriptomic datasets, related to Figure 4.

9

Supplementary table 7. Ingenuity Pathway Analysis predicted diseases and functions in Zone 1 astrocytes, FDR<0.1, related to Figure 5. Activation z-score, cortex and white matter; p-value, activation z-score, and gene lists by model.

10

Supplementary table 8. Zone 1 genes associated with the development of vasculature found in the extracellular region; WGCNA module membership and reactivity-associate gene significance scores, related to Figure 5.

11

Supplementary video 1. Example of mouse picking up, turning peanut butter-filled trough, related to Figure 7 and STAR Methods.

Download video file (41.8MB, mp4)

Highlights:

  • Post-stroke astrocyte reactivity shows region-dependent similarities and differences

  • A post-stroke transcriptional gene module is similarly regulated in other injuries

  • Cortical but not white matter astrocytes express pro-angiogenic genes post-stroke

  • Astrocytic Lamc1 is a cortical repair mechanism that can be induced in white matter

Acknowledgments

This work was supported by the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation (to S.T.C. and R.K.), the National Institutes of Health (to A.J.G.; F32NS087783), and the Larry L. Hillblom Foundation (to A.J.G.). We thank Gilles Bonvento for kindly sharing the miR124T cassette. Laser capture microscopy was performed in the Advanced Light Microscopy/Spectroscopy Facility at the California NanoSystems Institute at UCLA. We thank Jenna Kovsky, Chris Mullally, Meron Gebreyes, Gareema Agarwal, and Michal Machnicki for assistance with tissue processing and lentiviral packaging. We thank Giovanni Coppola for advice on the design of RiboTag experiments. We thank Qing Wang for assistance with RNAseq library preparation. Schematic diagrams created with Biorender.com.

Footnotes

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Declaration of interests

The authors declare no competing interests.

References

  • 1.Khakh BS, and Sofroniew MV (2015). Diversity of astrocyte functions and phenotypes in neural circuits. 18, 942–952. 10.1038/nn.4043. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Chung W-S, Baldwin KT, and Allen NJ (2024). Astrocyte Regulation of Synapse Formation, Maturation, and Elimination. Cold Spring Harb Perspect Biol, a041352. 10.1101/cshperspect.a041352. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Nagai J, Yu X, Papouin T, Cheong E, Freeman MR, Monk KR, Hastings MH, Haydon PG, Rowitch D, Shaham S, et al. (2021). Behaviorally consequential astrocytic regulation of neural circuits. Neuron 109, 576–596. 10.1016/j.neuron.2020.12.008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Díaz-Castro B, Robel S, and Mishra A (2023). Astrocyte Endfeet in Brain Function and Pathology: Open Questions. Annual Review of Neuroscience 46, 101–121. 10.1146/annurev-neuro-091922-031205. [DOI] [PubMed] [Google Scholar]
  • 5.Paisley CE, and Kay JN (2021). Seeing stars: Development and function of retinal astrocytes. Developmental Biology 478, 144–154. 10.1016/j.ydbio.2021.07.007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Cekanaviciute E, and Buckwalter MS (2016). Astrocytes: Integrative Regulators of Neuroinflammation in Stroke and Other Neurological Diseases. Neurotherapeutics, 1–17. 10.1007/s13311-016-0477-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Linnerbauer M, Wheeler MA, and Quintana FJ (2020). Astrocyte Crosstalk in CNS Inflammation. Neuron 108, 608–622. 10.1016/j.neuron.2020.08.012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Hasel P, Cooper ML, Marchildon AE, Rufen-Blanchette UA, Kim RD, Ma TC, Kang UJ, Chao MV, and Liddelow SA (2023). Defining the molecular identity and morphology of glia limitans superficialis astrocytes in mouse and human. Preprint at bioRxiv, 10.1101/2023.04.06.535893 https://doi.org/10.1101/2023.04.06.535893. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.O’Shea TM, Ao Y, Wang S, Ren Y, Cheng A, Kawaguchi R, Swarup V, and Sofroniew MV (2023). Border-forming wound repair astrocytes. Preprint at bioRxiv, 10.1101/2023.08.25.554857 https://doi.org/10.1101/2023.08.25.554857. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Sofroniew MV (2009). Molecular dissection of reactive astrogliosis and glial scar formation. Trends in Neurosciences 32, 638–647. 10.1016/j.tins.2009.08.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Barreto GE, Sun X, Xu L, and Giffard RG (2011). Astrocyte Proliferation Following Stroke in the Mouse Depends on Distance from the Infarct. PLoS ONE 6, e27881. 10.1371/journal.pone.0027881. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Burda JE, and Sofroniew MV (2014). Reactive Gliosis and the Multicellular Response to CNS Damage and Disease. Neuron 81, 229–248. 10.1016/j.neuron.2013.12.034. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Khakh BS, and Deneen B (2019). The Emerging Nature of Astrocyte Diversity. Annu. Rev. Neurosci 42, 187–207. 10.1146/annurev-neuro-070918-050443. [DOI] [PubMed] [Google Scholar]
  • 14.Köhler S, Winkler U, and Hirrlinger J (2021). Heterogeneity of Astrocytes in Grey and White Matter. Neurochem Res 46, 3–14. 10.1007/s11064-019-02926-x. [DOI] [PubMed] [Google Scholar]
  • 15.Sweid A, Hammoud B, Ramesh S, Wong D, Alexander TD, Weinberg JH, Deprince M, Dougherty J, Maamari DJ-M, Tjoumakaris S, et al. (2019). Acute ischaemic stroke interventions: large vessel occlusion and beyond. Stroke Vasc Neurol 5, 80–85. 10.1136/svn-2019-000262. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Pasi M, and Cordonnier C (2020). Clinical Relevance of Cerebral Small Vessel Diseases. Stroke 51, 47–53. 10.1161/STROKEAHA.119.024148. [DOI] [PubMed] [Google Scholar]
  • 17.Ng YS, Stein J, Ning M, and Black-Schaffer RM (2007). Comparison of Clinical Characteristics and Functional Outcomes of Ischemic Stroke in Different Vascular Territories. Stroke 38, 2309–2314. 10.1161/STROKEAHA.106.475483. [DOI] [PubMed] [Google Scholar]
  • 18.Beume L-A, Hieber M, Kaller CP, Nitschke K, Bardutzky J, Urbach H, Weiller C, and Rijntjes M (2018). Large Vessel Occlusion in Acute Stroke. Stroke 49, 2323–2329. 10.1161/STROKEAHA.118.022253. [DOI] [PubMed] [Google Scholar]
  • 19.Nogles TE, and Galuska MA (2024). Middle Cerebral Artery Stroke. In StatPearls (StatPearls Publishing; ). [PubMed] [Google Scholar]
  • 20.Duering M, Csanadi E, Gesierich B, Jouvent E, Hervé D, Seiler S, Belaroussi B, Ropele S, Schmidt R, Chabriat H, et al. (2013). Incident lacunes preferentially localize to the edge of white matter hyperintensities: insights into the pathophysiology of cerebral small vessel disease. Brain 136, 2717–2726. 10.1093/brain/awt184. [DOI] [PubMed] [Google Scholar]
  • 21.Inoue Y, Shue F, Bu G, and Kanekiyo T (2023). Pathophysiology and probable etiology of cerebral small vessel disease in vascular dementia and Alzheimer’s disease. Molecular Neurodegeneration 18, 46. 10.1186/s13024-023-00640-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Carmichael ST (2005). Rodent models of focal stroke: Size, mechanism, and purpose. Neurotherapeutics 2, 396–409. 10.1602/neurorx.2.3.396. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Rosenzweig S, and Carmichael ST (2013). Age-Dependent Exacerbation of White Matter Stroke Outcomes A Role for Oxidative Damage and Inflammatory Mediators. Stroke. 10.1161/STROKEAHA.113.001796/-/DC1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Dobkin BH, and Carmichael ST (2016). The Specific Requirements of Neural Repair Trials for Stroke. Neurorehabil Neural Repair 30, 470–478. 10.1177/1545968315604400. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Li H, Zhang N, Lin H-Y, Yu Y, Cai Q-Y, Ma L, and Ding S (2014). Histological, cellular and behavioral assessments of stroke outcomes after photothrombosis-induced ischemia in adult mice. BMC Neurosci 15, 58. 10.1186/1471-2202-15-58. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Shen J, Ishii Y, Xu G, Dang TC, Hamashima T, Matsushima T, Yamamoto S, Hattori Y, Takatsuru Y, Nabekura J, et al. (2012). PDGFR-β as a Positive Regulator of Tissue Repair in a Mouse Model of Focal Cerebral Ischemia. J Cereb Blood Flow Metab 32, 353–367. 10.1038/jcbfm.2011.136. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Williamson MR, Franzen RL, Fuertes CJA, Dunn AK, Drew MR, and Jones TA (2020). A Window of Vascular Plasticity Coupled to Behavioral Recovery after Stroke. J. Neurosci 40, 7651–7667. 10.1523/JNEUROSCI.1464-20.2020. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Li S, Overman JJ, Katsman D, Kozlov SV, Donnelly CJ, Twiss JL, Giger RJ, Coppola G, Geschwind DH, and Carmichael ST (2010). An age-related sprouting transcriptome provides molecular control of axonal sprouting after stroke. Nat Neurosci 13, 1496–1504. 10.1038/nn.2674. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Ohab JJ, Fleming S, Blesch A, and Carmichael ST (2006). A Neurovascular Niche for Neurogenesis after Stroke. Journal of Neuroscience 26, 13007–13016. 10.1523/JNEUROSCI.4323-06.2006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Jayaraj RL, Azimullah S, Beiram R, Jalal FY, and Rosenberg GA (2019). Neuroinflammation: friend and foe for ischemic stroke. J Neuroinflammation 16, 142. 10.1186/s12974-019-1516-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Gleichman AJ, Kawaguchi R, Sofroniew MV, and Carmichael ST (2023). A toolbox of astrocyte-specific, serotype-independent adeno-associated viral vectors using microRNA targeting sequences. Nat Commun 14, 7426. 10.1038/s41467-023-42746-w. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Marin MA, Gleichman AJ, Brumm AJ, and Carmichael ST (2023). Subcortical White Matter Stroke in the Mouse: Inducing Injury and Tracking Cellular Proliferation. Methods Mol. Biol 2616, 13–20. 10.1007/978-1-0716-2926-0_2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Cheng P, Alberts I, and Li X (2013). The role of ERK1/2 in the regulation of proliferation and differentiation of astrocytes in developing brain. International Journal of Developmental Neuroscience 31, 783–789. 10.1016/j.ijdevneu.2013.09.008. [DOI] [PubMed] [Google Scholar]
  • 34.Li J, Jia Z, Zhang Q, Dai J, Kong J, Fan Z, and Li G (2021). Inhibition of ERK1/2 phosphorylation attenuates spinal cord injury induced astrocyte activation and inflammation through negatively regulating aquaporin-4 in rats. Brain Research Bulletin 170, 162–173. 10.1016/j.brainresbull.2021.02.014. [DOI] [PubMed] [Google Scholar]
  • 35.Zamanian JL, Xu L, Foo LC, Nouri N, Zhou L, Giffard RG, and Barres BA (2012). Genomic Analysis of Reactive Astrogliosis. Journal of Neuroscience 32, 6391–6410. 10.1523/JNEUROSCI.6221-11.2012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Zhao R-Y, Wei P-J, Sun X, Zhang D-H, He Q-Y, Liu J, Chang J-L, Yang Y, and Guo Z-N (2023). Role of lipocalin 2 in stroke. Neurobiology of Disease 179, 106044. 10.1016/j.nbd.2023.106044. [DOI] [PubMed] [Google Scholar]
  • 37.Olsen ML, Campbell SC, McFerrin MB, Floyd CL, and Sontheimer H (2010). Spinal cord injury causes a wide-spread, persistent loss of Kir4.1 and glutamate transporter 1: benefit of 17β-oestradiol treatment. Brain 133, 1013–1025. 10.1093/brain/awq049. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Steiner E, Enzmann GU, Lin S, Ghavampour S, Hannocks M-J, Zuber B, Rüegg MA, Sorokin L, and Engelhardt B (2012). Loss of astrocyte polarization upon transient focal brain ischemia as a possible mechanism to counteract early edema formation. Glia 60, 1646–1659. 10.1002/glia.22383. [DOI] [PubMed] [Google Scholar]
  • 39.Pivonkova H, Benesova J, Butenko O, Chvatal A, and Anderova M (2010). Impact of global cerebral ischemia on K+ channel expression and membrane properties of glial cells in the rat hippocampus. Neurochem Int 57, 783–794. 10.1016/j.neuint.2010.08.016. [DOI] [PubMed] [Google Scholar]
  • 40.Friedman B, Schachtrup C, Tsai PS, Shih AY, Akassoglou K, Kleinfeld D, and Lyden PD (2009). Acute Vascular Disruption and Aquaporin 4 Loss After Stroke. Stroke 40, 2182–2190. 10.1161/STROKEAHA.108.523720. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Ren Z, Iliff JJ, Yang L, Yang J, Chen X, Chen MJ, Giese RN, Wang B, Shi X, and Nedergaard M (2013). “Hit & Run” model of closed-skull traumatic brain injury (TBI) reveals complex patterns of post-traumatic AQP4 dysregulation. Journal of Cerebral Blood Flow & Metabolism 33, 834–845. 10.1038/jcbfm.2013.30. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Raghavendra Rao VL, Bowen KK, and Dempsey RJ (2001). Transient Focal Cerebral Ischemia Down-Regulates Glutamate Transporters GLT-1 and EAAC1 Expression in Rat Brain. Neurochem Res 26, 497–502. 10.1023/A:1010956711295. [DOI] [PubMed] [Google Scholar]
  • 43.Takatsuru Y, Eto K, Kaneko R, Masuda H, Shimokawa N, Koibuchi N, and Nabekura J (2013). Critical Role of the Astrocyte for Functional Remodeling in Contralateral Hemisphere of Somatosensory Cortex after Stroke. Journal of Neuroscience 33, 4683–4692. 10.1523/JNEUROSCI.2657-12.2013. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Viswanathan S, Williams ME, Bloss EB, Stasevich TJ, Speer CM, Nern A, Pfeiffer BD, Hooks BM, Li W-P, English BP, et al. (2015). High-performance probes for light and electron microscopy. Nat Methods 12, 568–576. 10.1038/nmeth.3365. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Sanz E, Yang L, Su T, Morris DR, McKnight GS, and Amieux PS (2009). Cell-type-specific isolation of ribosome-associated mRNA from complex tissues. Proc. Natl. Acad. Sci. U.S.A 106, 13939–13944. 10.1073/pnas.0907143106. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Gregorian C, Nakashima J, Belle JL, Ohab J, Kim R, Liu A, Smith KB, Groszer M, Garcia AD, Sofroniew MV, et al. (2009). Pten Deletion in Adult Neural Stem/Progenitor Cells Enhances Constitutive Neurogenesis. J. Neurosci 29, 1874–1886. 10.1523/JNEUROSCI.3095-08.2009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Anderson MA, Burda JE, Ren Y, Ao Y, O’Shea TM, Kawaguchi R, Coppola G, Khakh BS, Deming TJ, and Sofroniew MV (2016). Astrocyte scar formation aids central nervous system axon regeneration. Nature 532, 195–200. 10.1038/nature17623. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, et al. (2005). Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. U.S.A 102, 15545–15550. 10.1073/pnas.0506580102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Langfelder P, and Horvath S (2008). WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics 9, 559. 10.1186/1471-2105-9-559. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Mi H, Muruganujan A, Casagrande JT, and Thomas PD (2013). Large-scale gene function analysis with the PANTHER classification system. Nat Protoc 8, 1551–1566. 10.1038/nprot.2013.092. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Zhang Y, Chen K, Sloan SA, Bennett ML, Scholze AR, O’Keeffe S, Phatnani HP, Guarnieri P, Caneda C, Ruderisch N, et al. (2014). An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. Journal of Neuroscience 34, 11929–11947. 10.1523/JNEUROSCI.1860-14.2014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Hernandez VG, Lechtenberg KJ, Peterson TC, Zhu L, Lucas TA, Bradshaw KP, Owah JO, Dorsey AI, Gentles AJ, and Buckwalter MS (2023). Translatome analysis reveals microglia and astrocytes to be distinct regulators of inflammation in the hyperacute and acute phases after stroke. Glia 71, 1960–1984. 10.1002/glia.24377. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Sirko S, Irmler M, Gascón S, Bek S, Schneider S, Dimou L, Obermann J, De Souza Paiva D, Poirier F, Beckers J, et al. (2015). Astrocyte reactivity after brain injury—: The role of galectins 1 and 3. Glia 63, 2340–2361. 10.1002/glia.22898. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Hasel P, Rose IVL, Sadick JS, Kim RD, and Liddelow SA (2021). Neuroinflammatory astrocyte subtypes in the mouse brain. Nat Neurosci 24, 1475–1487. 10.1038/s41593-021-00905-6. [DOI] [PubMed] [Google Scholar]
  • 55.Boisvert MM, Erikson GA, Shokhirev MN, and Allen NJ (2018). The Aging Astrocyte Transcriptome from Multiple Regions of the Mouse Brain. Cell Reports 22, 269–285. 10.1016/j.celrep.2017.12.039. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Jiwaji Z, Tiwari SS, Avilés-Reyes RX, Hooley M, Hampton D, Torvell M, Johnson DA, McQueen J, Baxter P, Sabari-Sankar K, et al. (2022). Reactive astrocytes acquire neuroprotective as well as deleterious signatures in response to Tau and Aß pathology. Nat Commun 13, 135. 10.1038/s41467-021-27702-w. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Diaz-Castro B, Gangwani MR, Yu X, Coppola G, and Khakh BS (2019). Astrocyte molecular signatures in Huntington’s disease. Sci Transl Med 11, eaaw8546. 10.1126/scitranslmed.aaw8546. [DOI] [PubMed] [Google Scholar]
  • 58.Burda JE, O’Shea TM, Ao Y, Suresh KB, Wang S, Bernstein AM, Chandra A, Deverasetty S, Kawaguchi R, Kim JH, et al. (2022). Divergent transcriptional regulation of astrocyte reactivity across disorders. Nature 606, 557–564. 10.1038/s41586-022-04739-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.Wu O, Cloonan L, Mocking SJT, Bouts MJRJ, Copen WA, Cougo-Pinto PT, Fitzpatrick K, Kanakis A, Schaefer PW, Rosand J, et al. (2015). Role of Acute Lesion Topography in Initial Ischemic Stroke Severity and Long-Term Functional Outcomes. Stroke 46, 2438–2444. 10.1161/STROKEAHA.115.009643. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60.Williamson MR, Fuertes CJA, Dunn AK, Drew MR, and Jones TA (2021). Reactive astrocytes facilitate vascular repair and remodeling after stroke. CellReports 35, 109048. 10.1016/j.celrep.2021.109048. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61.Hayakawa K, Seo JH, Miyamoto N, Pham L-DD, Navaratna D, Lo EH, and Arai K (2017). Brain Angiogenesis After Stroke. In Biochemical Basis and Therapeutic Implications of Angiogenesis Advances in Biochemistry in Health and Disease., Mehta JL, Mathur P, and Dhalla NS, eds. (Springer International Publishing; ), pp. 473–494. 10.1007/978-3-319-61115-0_21. [DOI] [Google Scholar]
  • 62.Ding L, Hou B, Zang J, Su T, Feng F, Zhu Z, and Peng B (2023). Imaging of Angiogenesis in White Matter Hyperintensities. Journal of the American Heart Association 12, e028569. 10.1161/JAHA.122.028569. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.Mills WA, Woo AM, Jiang S, Martin J, Surendran D, Bergstresser M, Kimbrough IF, Eyo UB, Sofroniew MV, and Sontheimer H (2022). Astrocyte plasticity in mice ensures continued endfoot coverage of cerebral blood vessels following injury and declines with age. Nat Commun 13, 1794. 10.1038/s41467-022-29475-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64.Ponce ML, Nomizu M, Delgado MC, Kuratomi Y, Hoffman MP, Powell S, Yamada Y, Kleinman HK, and Malinda KM (1999). Identification of Endothelial Cell Binding Sites on the Laminin γ1 Chain. Circulation Research 84, 688–694. 10.1161/01.RES.84.6.688. [DOI] [PubMed] [Google Scholar]
  • 65.Buga AM, Margaritescu C, Scholz CJ, Radu E, Zelenak C, and Popa-Wagner A (2014). Transcriptomics of Post-Stroke Angiogenesis in the Aged Brain. Front. Aging Neurosci 6. 10.3389/fnagi.2014.00044. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 66.Hartmann DA, Berthiaume A-A, Grant RI, Harrill SA, Koski T, Tieu T, McDowell KP, Faino AV, Kelly AL, and Shih AY (2021). Brain capillary pericytes exert a substantial but slow influence on blood flow. Nat Neurosci 24, 633–645. 10.1038/s41593-020-00793-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 67.Lengfeld JE, Lutz SE, Smith JR, Diaconu C, Scott C, Kofman SB, Choi C, Walsh CM, Raine CS, Agalliu I, et al. (2017). Endothelial Wnt/β-catenin signaling reduces immune cell infiltration in multiple sclerosis. Proc. Natl. Acad. Sci. U.S.A 114. 10.1073/pnas.1609905114. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68.Cavaglia M, Dombrowski SM, Drazba J, Vasanji A, Bokesch PM, and Janigro D (2001). Regional variation in brain capillary density and vascular response to ischemia. Brain Research 910, 81–93. 10.1016/S0006-8993(01)02637-3. [DOI] [PubMed] [Google Scholar]
  • 69.Dias DO, Kim H, Holl D, Solnestam BW, Lundeberg J, Carlén M, Göritz C, and Frisén J (2018). Reducing Pericyte-Derived Scarring Promotes Recovery after Spinal Cord Injury. Cell, 1–36. 10.1016/j.cell.2018.02.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 70.Yoshioka N, Hisanaga S-I, and Kawano H (2010). Suppression of fibrotic scar formation promotes axonal regeneration without disturbing blood-brain barrier repair and withdrawal of leukocytes after traumatic brain injury. Journal of Comparative Neurology 518, 3867–3881. 10.1002/cne.22431. [DOI] [PubMed] [Google Scholar]
  • 71.Zhu Y, Soderblom C, Krishnan V, Ashbaugh J, Bethea JR, and Lee JK (2015). Hematogenous macrophage depletion reduces the fibrotic scar and increases axonal growth after spinal cord injury. Neurobiology of Disease 74, 114–125. 10.1016/j.nbd.2014.10.024. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 72.Bai J, Zheng A, Ha Y, Xu X, Yu Y, Lu Y, Zheng S, Shen Z, Luo B, and Jie W (2022). Comprehensive analysis of LAMC1 expression and prognostic value in kidney renal papillary cell carcinoma and clear cell carcinoma. Front. Mol. Biosci 9. 10.3389/fmolb.2022.988777. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 73.Heindl S, Ricci A, Carofiglio O, Zhou Q, Arzberger T, Lenart N, Franzmeier N, Hortobagyi T, Nelson PT, Stowe AM, et al. (2021). Chronic T cell proliferation in brains after stroke could interfere with the efficacy of immunotherapies. Journal of Experimental Medicine 218, e20202411. 10.1084/jem.20202411. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 74.Shi L, Sun Z, Su W, Xu F, Xie D, Zhang Q, Dai X, Iyer K, Hitchens TK, Foley LM, et al. (2021). Treg cell-derived osteopontin promotes microglia-mediated white matter repair after ischemic stroke. Immunity 54, 1527–1542.e8. 10.1016/j.immuni.2021.04.022. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 75.Ito M, Komai K, Mise-Omata S, Iizuka-Koga M, Noguchi Y, Kondo T, Sakai R, Matsuo K, Nakayama T, Yoshie O, et al. (2019). Brain regulatory T cells suppress astrogliosis and potentiate neurological recovery. Nature 565, 246–250. 10.1038/s41586-018-0824-5. [DOI] [PubMed] [Google Scholar]
  • 76.Dombrowski Y, O’Hagan T, Dittmer M, Penalva R, Mayoral SR, Bankhead P, Fleville S, Eleftheriadis G, Zhao C, Naughton M, et al. (2017). Regulatory T cells promote myelin regeneration in the central nervous system. Nat Neurosci 20, 674–680. 10.1038/nn.4528. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 77.Sozmen EG, Hinman JD, and Carmichael ST (2012). Models that matter: white matter stroke models. Neurotherapeutics 9, 349–358. 10.1007/s13311-012-0106-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 78.Vallance P, and Leiper J (2002). Blocking NO synthesis: how, where and why? Nat Rev Drug Discov 1, 939–950. 10.1038/nrd960. [DOI] [PubMed] [Google Scholar]
  • 79.Tricoire L, and Vitalis T (2012). Neuronal nitric oxide synthase expressing neurons: a journey from birth to neuronal circuits. Front. Neural Circuits 6. 10.3389/fncir.2012.00082. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 80.Li G-W, Burkhardt D, Gross C, and Weissman JS (2014). Quantifying Absolute Protein Synthesis Rates Reveals Principles Underlying Allocation of Cellular Resources. Cell 157, 624–635. 10.1016/j.cell.2014.02.033. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 81.Haimon Z, Volaski A, Orthgiess J, Boura-Halfon S, Varol D, Shemer A, Yona S, Zuckerman B, David E, Chappell-Maor L, et al. (2018). Re-evaluating microglia expression profiles using RiboTag and cell isolation strategies. Nature Immunology, 1–13. 10.1038/s41590-018-0110-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 82.Kim RD, Marchildon AE, Frazel PW, Hasel P, Guo AX, and Liddelow S (2023). Temporal and spatial analysis of astrocytes following stroke identifies novel drivers of reactivity. Preprint at bioRxiv, 10.1101/2023.11.12.566710 https://doi.org/10.1101/2023.11.12.566710. [DOI] [Google Scholar]
  • 83.Scott EY, Safarian N, Casasbuenas DL, Dryden M, Tockovska T, Ali S, Peng J, Daniele E, Nie Xin Lim I, Bang KWA, et al. (2024). Integrating single-cell and spatially resolved transcriptomic strategies to survey the astrocyte response to stroke in male mice. Nat Commun 15, 1584. 10.1038/s41467-024-45821-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 84.Stokowska A, Aswendt M, Zucha D, Lohmann S, Wieters F, Suarez JM, Atkins AL, Li Y, Miteva M, Lewin J, et al. (2023). Complement C3a treatment accelerates recovery after stroke via modulation of astrocyte reactivity and cortical connectivity. J Clin Invest 133. 10.1172/JCI162253. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 85.Escartin C, Galea E, Lakatos A, O’Callaghan JP, Petzold GC, Serrano-Pozo A, Steinhäuser C, Volterra A, Carmignoto G, Agarwal A, et al. (2021). Reactive astrocyte nomenclature, definitions, and future directions. Nat Neurosci 24, 312–325. 10.1038/s41593-020-00783-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 86.Sirko S, Schichor C, Della Vecchia P, Metzger F, Sonsalla G, Simon T, Bürkle M, Kalpazidou S, Ninkovic J, Masserdotti G, et al. (2023). Injury-specific factors in the cerebrospinal fluid regulate astrocyte plasticity in the human brain. Nat Med 29, 3149–3161. 10.1038/s41591-023-02644-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 87.Collyer E, Boyle BR, Gomez-Galvez Y, Iacovitti L, and Blanco-Suarez E (2023). Absence of chordin-like 1 aids motor recovery in a mouse model of stroke. Experimental Neurology 370, 114548. 10.1016/j.expneurol.2023.114548. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 88.Miyamoto N, Maki T, Shindo A, Liang AC, Maeda M, Egawa N, Itoh K, Lo EK, Lok J, Ihara M, et al. (2015). Astrocytes Promote Oligodendrogenesis after White Matter Damage via Brain-Derived Neurotrophic Factor. Journal of Neuroscience 35, 14002–14008. 10.1523/JNEUROSCI.1592-15.2015. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 89.Nguyen H, Zerimech S, and Baltan S (2021). Astrocyte Mitochondria in White-Matter Injury. Neurochem Res 46, 2696–2714. 10.1007/s11064-021-03239-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 90.Seeker LA, Bestard-Cuche N, Jäkel S, Kazakou N-L, Bøstrand SMK, Wagstaff LJ, Cholewa-Waclaw J, Kilpatrick AM, Van Bruggen D, Kabbe M, et al. (2023). Brain matters: unveiling the distinct contributions of region, age, and sex to glia diversity and CNS function. Acta Neuropathologica Communications 11, 84. 10.1186/s40478-023-01568-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 91.Damisah EC, Hill RA, Rai A, Chen F, Rothlin CV, Ghosh S, and Grutzendler J (2020). Astrocytes and microglia play orchestrated roles and respect phagocytic territories during neuronal corpse removal in vivo. Science Advances 6, eaba3239. 10.1126/sciadv.aba3239. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 92.Chung W-S, Clarke LE, Wang GX, Stafford BK, Sher A, Chakraborty C, Joung J, Foo LC, Thompson A, Chen C, et al. (2013). Astrocytes mediate synapse elimination through MEGF10 and MERTK pathways. Nature. 10.1038/nature12776. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 93.Heneka MT, van der Flier WM, Jessen F, Hoozemanns J, Thal DR, Boche D, Brosseron F, Teunissen C, Zetterberg H, Jacobs AH, et al. (2024). Neuroinflammation in Alzheimer disease. Nat Rev Immunol, 1–32. 10.1038/s41577-024-01104-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 94.Surakka I, Wu K-H, Hornsby W, Wolford BN, Shen F, Zhou W, Huffman JE, Pandit A, Hu Y, Brumpton B, et al. (2023). Multi-ancestry meta-analysis identifies 5 novel loci for ischemic stroke and reveals heterogeneity of effects between sexes and ancestries. Cell Genomics 3, 100345. 10.1016/j.xgen.2023.100345. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 95.Soto JS, Jami-Alahmadi Y, Chacon J, Moye SL, Diaz-Castro B, Wohlschlegel JA, and Khakh BS (2023). Astrocyte–neuron subproteomes and obsessive–compulsive disorder mechanisms. Nature 616, 764–773. 10.1038/s41586-023-05927-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 96.Kwakkel G, Kollen B, and Twisk J (2006). Impact of Time on Improvement of Outcome After Stroke. Stroke 37, 2348–2353. 10.1161/01.STR.0000238594.91938.1e. [DOI] [PubMed] [Google Scholar]
  • 97.Ramsey LE, Siegel JS, Lang CE, Strube M, Shulman GL, and Corbetta M (2017). Behavioural clusters and predictors of performance during recovery from stroke. Nat Hum Behav 1, 1–10. 10.1038/s41562-016-0038. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 98.Ryu W-S, Woo S-H, Schellingerhout D, Jang MU, Park K-J, Hong K-S, Jeong S-W, Na J-Y, Cho K-H, Kim J-T, et al. (2017). Stroke outcomes are worse with larger leukoaraiosis volumes. Brain 140, 158–170. 10.1093/brain/aww259. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 99.Giese A-K, Schirmer MD, Dalca AV, Sridharan R, Donahue KL, Nardin M, Irie R, McIntosh EC, Mocking SJT, Xu H, et al. (2020). White matter hyperintensity burden in acute stroke patients differs by ischemic stroke subtype. Neurology 95, e79–e88. 10.1212/WNL.0000000000009728. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 100.Wang Y, Liu G, Hong D, Chen F, Ji X, and Cao G (2016). White matter injury in ischemic stroke. Progress in Neurobiology 141, 45–60. 10.1016/j.pneurobio.2016.04.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 101.Regenhardt RW, Das AS, Lo EH, and Caplan LR (2018). Advances in Understanding the Pathophysiology of Lacunar Stroke: A Review. JAMA Neurology 75, 1273–1281. 10.1001/jamaneurol.2018.1073. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 102.Loos CMJ, Makin SDJ, Staals J, Dennis MS, van Oostenbrugge RJ, and Wardlaw JM (2018). Long-Term Morphological Changes of Symptomatic Lacunar Infarcts and Surrounding White Matter on Structural Magnetic Resonance Imaging. Stroke 49, 1183–1188. 10.1161/STROKEAHA.117.020495. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 103.Enomoto M, Bunge MB, and Tsoulfas P (2013). A multifunctional neurotrophin with reduced affinity to p75NTR enhances transplanted Schwann cell survival and axon growth after spinal cord injury. Experimental Neurology 248, 170–182. 10.1016/j.expneurol.2013.06.013. [DOI] [PubMed] [Google Scholar]
  • 104.Madisen L, Garner AR, Shimaoka D, Chuong AS, Klapoetke NC, Li L, van der Bourg A, Niino Y, Egolf L, Monetti C, et al. (2015). Transgenic Mice for Intersectional Targeting of Neural Sensors and Effectors with High Specificity and Performance. Neuron 85, 942–958. 10.1016/j.neuron.2015.02.022. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 105.Platt RJ, Chen S, Zhou Y, Yim MJ, Swiech L, Kempton HR, Dahlman JE, Parnas O, Eisenhaure TM, Jovanovic M, et al. (2014). CRISPR-Cas9 knockin mice for genome editing and cancer modeling. Cell 159, 440–455. 10.1016/j.cell.2014.09.014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 106.Strecker J, Jones S, Koopal B, Schmid-Burgk J, Zetsche B, Gao L, Makarova KS, Koonin EV, and Zhang F (2019). Engineering of CRISPR-Cas12b for human genome editing. Nature Communications 10, 212–218. 10.1038/s41467-018-08224-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 107.Campeau E, Ruhl VE, Rodier F, Smith CL, Rahmberg BL, Fuss JO, Campisi J, Yaswen P, Cooper PK, and Kaufman PD (2009). A versatile viral system for expression and depletion of proteins in mammalian cells. PLoS One 4, e6529. 10.1371/journal.pone.0006529. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 108.Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, Batut P, Chaisson M, and Gingeras TR (2013). STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15–21. 10.1093/bioinformatics/bts635. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 109.Putri GH, Anders S, Pyl PT, Pimanda JE, and Zanini F (2022). Analysing high-throughput sequencing data in Python with HTSeq 2.0. Bioinformatics 38, 2943–2945. 10.1093/bioinformatics/btac166. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 110.The Galaxy Community (2022). The Galaxy platform for accessible, reproducible and collaborative biomedical analyses: 2022 update. Nucleic Acids Research 50, W345–W351. 10.1093/nar/gkac247. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 111.Tao J, Wu H, Lin Q, Wei W, Lu X-H, Cantle JP, Ao Y, Olsen RW, Yang XW, Mody I, et al. (2011). Deletion of Astroglial Dicer Causes Non-Cell-Autonomous Neuronal Dysfunction and Degeneration. J. Neurosci 31, 8306–8319. 10.1523/JNEUROSCI.0567-11.2011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 112.Molumby MJ, Keeler AB, and Weiner JA (2016). Homophilic Protocadherin Cell-Cell Interactions Promote Dendrite Complexity. Cell Reports 15, 1037–1050. 10.1016/j.celrep.2016.03.093. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 113.Gibson DG, Young L, Chuang R-Y, Venter JC, Hutchison CA, and Smith HO (2009). Enzymatic assembly of DNA molecules up to several hundred kilobases. Nat Methods 6, 343–345. 10.1038/nmeth.1318. [DOI] [PubMed] [Google Scholar]
  • 114.Colin A, Faideau M, Dufour N, Auregan G, Hassig R, Andrieu T, Brouillet E, Hantraye P, Bonvento G, and Déglon N (2009). Engineered lentiviral vector targeting astrocytes In vivo. Glia 57, 667–679. 10.1002/glia.20795. [DOI] [PubMed] [Google Scholar]
  • 115.Gao Y, Hisey E, Bradshaw TWA, Erata E, Brown WE, Courtland JL, Uezu A, Xiang Y, Diao Y, and Soderling SH (2019). Plug-and-Play Protein Modification Using Homology- Independent Universal Genome Engineering. Neuron 103, 583–597.e8. 10.1016/j.neuron.2019.05.047. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 116.Bae S, Park J, and Kim J-S (2014). Cas-OFFinder: a fast and versatile algorithm that searches for potential off-target sites of Cas9 RNA-guided endonucleases. Bioinformatics 30, 1473–1475. 10.1093/bioinformatics/btu048. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 117.Shigetomi E, Kracun S, Sofroniew MV, and Khakh BS (2010). A genetically targeted optical sensor to monitor calcium signals in astrocyte processes. Nat Neurosci 13, 759–766. 10.1038/nn.2557. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 118.Challis RC, Ravindra Kumar S, Chan KY, Challis C, Beadle K, Jang MJ, Kim HM, Rajendran PS, Tompkins JD, Shivkumar K, et al. (2019). Systemic AAV vectors for widespread and targeted gene delivery in rodents. Nat Protoc 14, 379–414. 10.1038/s41596-018-0097-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 119.Chan KY, Jang MJ, Yoo BB, Greenbaum A, Ravi N, Wu W-L, Sánchez-Guardado L, Lois C, Mazmanian SK, Deverman BE, et al. (2017). Engineered AAVs for efficient noninvasive gene delivery to the central and peripheral nervous systems. Nat Neurosci 20, 1172–1179. 10.1038/nn.4593. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 120.Khodosevich K, Inta D, Seeburg PH, and Monyer H (2007). Gene Expression Analysis of In Vivo Fluorescent Cells. PLoS ONE 2, e1151. 10.1371/journal.pone.0001151.t002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 121.Sanz E, Bean JC, Carey DP, Quintana A, and McKnight GS (2019). RiboTag: Ribosomal Tagging Strategy to Analyze Cell-Type-Specific mRNA Expression In Vivo. Current Protocols in Neuroscience 88. 10.1002/cpns.77. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 122.Law CW, Chen Y, Shi W, and Smyth GK (2014). voom: precision weights unlock linear model analysis tools for RNA-seq read counts. Genome Biology 15, R29. 10.1186/gb-2014-15-2-r29. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 123.Mootha VK, Lindgren CM, Eriksson K-F, Subramanian A, Sihag S, Lehar J, Puigserver P, Carlsson E, Ridderstråle M, Laurila E, et al. (2003). PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 34, 267–273. 10.1038/ng1180. [DOI] [PubMed] [Google Scholar]
  • 124.Hulsen T (2022). DeepVenn -- a web application for the creation of area-proportional Venn diagrams using the deep learning framework Tensorflow.js. Preprint at arXiv, 10.48550/arXiv.2210.04597 https://doi.org/10.48550/arXiv.2210.04597. [DOI] [Google Scholar]
  • 125.Pomaznoy M, Ha B, and Peters B (2018). GOnet: a tool for interactive Gene Ontology analysis. BMC Bioinformatics 19, 470. 10.1186/s12859-018-2533-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 126.Choi HMT, Schwarzkopf M, Fornace ME, Acharya A, Artavanis G, Stegmaier J, Cunha A, and Pierce NA (2018). Third-generation in situhybridization chain reaction: multiplexed, quantitative, sensitive, versatile, robust. Development 145, dev165753–122. 10.1242/dev.165753. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 127.Hoffmann C, Moreau F, Moes M, Luthold C, Dieterle M, Goretti E, Neumann K, Steinmetz A, and Thomas C (2014). Human Muscle LIM Protein Dimerizes along the Actin Cytoskeleton and Cross-Links Actin Filaments. Mol Cell Biol 34, 3053–3065. 10.1128/MCB.00651-14. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 128.Nicolas N, and Roux E (2021). 3D Imaging and Quantitative Characterization of Mouse Capillary Coronary Network Architecture. Biology (Basel) 10, 306. 10.3390/biology10040306. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

1
2

Supplementary file 1. .stl file for 3D-printed troughs, related to Figure 7 and STAR Methods.

3

Supplementary table 1. Differentially expressed genes in cortical stroke zones, FDR<0.1, related to Figure 3.

4

Supplementary table 2. Differentially expressed genes in white matter stroke zones, FDR<0.1, related to Figure 3.

5

Supplementary table 3. Gene Set Enrichment Analysis, related to Figure 3. Gene Ontology gene sets associated with zones 1 and 2, cortical and white matter stroke models, FDR <0.05. ES: enrichment score. NES: normalized enrichment score. NOM p-val: nominal p-value. FDR q-val: false discovery rate.

6

Supplementary table 4. Weighted Gene Correlation Network Analysis, related to Figure 4. All genes, module membership and reactivity-associated gene significance scores.

7

Supplementary table 5. GO biological processes enriched in the magenta module, related to Figure 4.

8

Supplementary table 6. Correlation of magenta module gene GS.reactivity scores with magenta module gene expression levels in other reactive astrocyte transcriptomic datasets, related to Figure 4.

9

Supplementary table 7. Ingenuity Pathway Analysis predicted diseases and functions in Zone 1 astrocytes, FDR<0.1, related to Figure 5. Activation z-score, cortex and white matter; p-value, activation z-score, and gene lists by model.

10

Supplementary table 8. Zone 1 genes associated with the development of vasculature found in the extracellular region; WGCNA module membership and reactivity-associate gene significance scores, related to Figure 5.

11

Supplementary video 1. Example of mouse picking up, turning peanut butter-filled trough, related to Figure 7 and STAR Methods.

Download video file (41.8MB, mp4)

Data Availability Statement

RNAseq data generated in this study are available through the Gene Expression Omnibus (GEO) with accession number GSE263986. Accession numbers for publicly available data analyzed for this study are listed in the key resources table. This paper does not report original code. Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request.

Key resource table

REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Rat anti-GFAP Thermo Fisher Scientific Cat #13-0300; RRID: AB_2532994
Rabbit anti-Iba1 FUJIFILM Wako Pure Chemical Corporation Cat# 019-19741, RRID:AB_839504
Goat anti-AldoC Santa Cruz Biotechnology Cat# sc-12066, RRID:AB_2226594
Rabbit anti-phosphoERK Cell Signaling Technology Cat# 4370, RRID:AB_2315112
Rabbit anti-Aldh1l1 Abcam Cat# ab87117, RRID:AB_10712968
Goat anti-Lcn2 R and D Systems Cat# AF1857, RRID:AB_355022
Mouse anti-Ki67 BD Biosciences Cat# 556003, RRID:AB_396287
Rat biotinylated anti-Ki67 Thermo Fisher Scientific Cat# 13-5698-80, RRID:AB_2572793
Rabbit anti-Kir4.1 Alomone Labs Cat# APC-035, RRID:AB_2040120
Rabbit anti-Aqp4 Millipore Cat# AB3594, RRID:AB_91530
Guinea pig anti-Glt1 Frontier Institute Cat# GLT1-GP, RRID:AB_2571720
Rabbit anti-FLAG Thermo Fisher Scientific Cat# PA1-984B, RRID:AB_347227
Chicken anti-V5 Abcam Cat# ab9113, RRID:AB_307022
Human anti-V5 Absolute Antibodies Cat# Ab00136-10.0, RRID:AB_3678832
Goat anti-Myc Abcam Cat# ab19234, RRID:AB_731663
Rat anti-HA Roche Cat# 11867423, RRID:AB_2314621
Sheep anti-Trem2 R and D Systems Cat# AF1729, RRID:AB_354956
Rat anti-CD31 BD Biosciences Cat# 550274, RRID:AB_393571
Rabbit anti-Myc, 488 labeled Biotium Cat# 20436 RRID:AB_3094486
Rabbit anti-Myc, 543 labeled Biotium Cat# 20437, RRID:AB_3095610
Rabbit anti-FLAG, 543 labeled Biotium Cat# 20433, RRID:AB_3095611
Rabbit anti-Col1a1 Abcam Cat# ab21286, RRID:AB_446161
Mouse anti-NF160 Abcam Cat# ab7794, RRID:AB_306083
Chicken anti-GFAP Rockland Cat# 200-901-D60, RRID:AB_11181163
Rabbit anti-CD3 Cell Signaling Cat# 78588, RRID:AB_2889902
Rat anti-Foxp3 Thermo Fisher Scientific Cat# 14-5773-82, RRID:AB_467576
Mouse anti-SMA Millipore Sigma Cat# A5228, RRID:AB_262054
Goat anti-MBP Neuromics Cat# GT22104, RRID:AB_3678833
Bacterial and virus strains
NEB Stable Competent E. coli New England Biolabs Cat #C3040H
Lentivirus, GfaABC1D-lck-smFLAG-miR124T This study N/A
Lentivirus, GfaABC1D-lck-smMyc-miR124T This study N/A
Lentivirus, GfaABC1D-lck-smV5-miR124T This study N/A
Lentivirus, GfaABC1D-Lamc1-FLAG-miR124T This study N/A
AAV, GfaABC1D-BhCas12b-miR124T This study N/A
AAV, U6-negative control gDNA-GfaABC1D-lck-smMyc-miR124T This study N/A
AAV, U6-Lamc1 gDNA 1-Lamc1 gDNA 2-GfaABC1D-lck-smMyc-miR124T This study N/A
AAV, GfaABC1D-lck-smV5-miR124T This study N/A
Chemicals, peptides, and recombinant proteins
2’-Deoxy-5-ethynyluridine (EdU) Biosynth Carbosynth Cat #NE08701
Sulfo-cyanine3 azide Lumiprobe Cat #D1330
Sulfo-cyanine5 azide Lumiprobe Cat #C3330
Mouse-on-mouse block Vector Labs Cat #MKB-2213
HCR probe: Slc1a3, hairpin B3 Molecular Instruments N/A
HCR probe: B2m, hairpin B1 Molecular Instruments N/A
HCR probe: Ifitm3, hairpin B1 Molecular Instruments N/A
HCR probe: Lamc1, hairpin B1 Molecular Instruments N/A
HCR probe: Cas12b, hairpin B4 Molecular Instruments N/A
HCR probe: Bcas1, hairpin B1 Molecular Instruments N/A
Probe hybridization buffer Molecular Instruments N/A
Probe wash buffer Molecular Instruments N/A
Amplification buffer Molecular Instruments N/A
Hairpin B3-488, 1 and 2 Molecular Instruments N/A
Hairpin B1-647, 1 and 2 Molecular Instruments N/A
Hairpin B4-546, 1 and 2 Molecular Instruments N/A
TrueView Autofluorescence Quenching Kit Vector Labs Cat #SP-8400-15
Fluoro-Gel Mounting Medium Electron Microscopy Services Cat# 17985-30
DPX Mounting Medium Electron Microscopy Services Cat #13512
Poly-D-lysine Sigma Aldrich Cat #P6407
DMEM media + GlutaMAX, glucose, and pyruvate Gibco Cat #10569
Heat-inactivated FBS Gibco Cat #16140-071
Polyethylenimine (PEI) Polysciences Cat #23966-1
Caffeine Sigma Aldrich Cat #C0750
Salt-active nuclease ArcticZymes Cat #70910-202
Pluronic F-68 Gibco Cat #24040-032
HiFi DNA Assembly Master Mix New England Biolabs Cat #E2621L
TransIT-X2 Dynamic Delivery System Mirus Bio Cat #MIR 6004
G418 Invivogen Cat #ANTGN1
Biocytin-TMR Thermo Fisher Scientific Cat #T12921
Albumin-647 Thermo Fisher Scientific Cat #A34785
Critical commercial assays
Mix-n-Stain™ Biotin Antibody Labeling Kit Biotium Cat #92266
Lenti-X p24 Rapid Titer Kit Takara Cat # 631476
Alt-R Genome Editing Detection Kit Integrated DNA Technologies Cat #1075932
TruSeq RNA Library Prep Kit with Ribo-Zero Illumina Cat #RS-122-2202
Deposited data
Input and immunoprecipitated RNA-seq, cortical and white matter stroke This study GEO: GSE263986
Spinal cord injury astrocytes Anderson et al.47 GEO: GSE76097
Stab wound astrocytes Sirko et al.53 GEO: GSE66370
Lipopolysaccharide-induced astrocytes Hasel et al.54 GEO: GSE148610
MCAO ipsilesional astrocytes Zamanian et al.35 GEO: GSE35338
Aged motor cortex astrocytes Boisvert et al.55 GEO: GSE99791
Alzheimer’s disease model astrocytes Jiwaji et al.56 European Nucleotide Archive: E-MTAB-10985
Huntington’s disease model astrocytes Diaz Castro et al.57 GEO: GSE124846
Experimental models: Cell lines
HEK-293 ATCC Cat #CRL-3216, RRID:CVCL_0063
SVEC4-10 ATCC Cat #CRL-2181, RRID:CVCL_4393
Experimental models: Organisms/strains
B6.Cg-Tg(Gfap-cre)77.6Mvs/2J Gregorian et al.46 RRID:IMSR_JAX:02 4098
B6N.129-Rpl22tm1.1Psam/J Sanz et al.45 RRID:IMSR_JAX:01 1029
C57BL/6J Jackson Laboratory RRID:IMSR_JAX:00 0664
Oligonucleotides
Cas12b titering primers: Fwd, GCTCTGAAGGCTCTGGAACA; Rev, GATTTCCCGCCAGCCTCTAA This study N/A
hGH titering primers: Fwd, CCTGGGTTCAAGCGATTCT; Rev, CAGCCTGGCCAATATGGT Gleichman et al.31 N/A
Negative control gDNA: GACGCTTCCGAGTACGGTACAGC This study N/A
Lamc1 gDNA 1: CTTATCAGTACTACAGTGGGTCC This study N/A
Lamc1 gDNA 2: ATCAGTACACAAGGCCTGCTGCT This study N/A
Recombinant DNA
Lentivirus backbone: pLenti-MP2 Pantelis Tsoulfas103 Addgene #36097
AAV backbone: AAV-pmSyn1-EBFP-Cre Hongkui Zeng104 Addgene #51507
AAV:ITR-U6-sgRNA(Kras)-U6-sgRNA(p53)-U6-sgRNA(Lkb1)-pEFS-Rluc-2A-Cre-shortPA-KrasG12D_HDRdonor-ITR (AAV-KPL) Feng Zhang105 Addgene #60224
pCAG_smFP FLAG Loren Looger44 Addgene #59756
pCAG_smFP V5 Loren Looger44 Addgene #59758
pCAG_smFP Myc Loren Looger44 Addgene #59757
pZ149-pcDNA3-BhCas12b_v4 Feng Zhang106 Addgene #122446
pLenti CMV GFP Neo (657-2) Eric Campeau and Paul Kaufman107 Addgene #17447
Lamc1 Transomic Technologies Cat #BC165945
Software and algorithms
ImageJ National Institutes of Health RRID:SCR_014210
GraphPad Prism 8 GraphPad Software RRID:SCR_002798
R v4.3.2 R core team RRID:SCR_001905
Nikon NIS Elements Nikon Instruments RRID:SCR_014329
Imaris Bitplane RRID:SCR_007370
STAR 2.4.0 Dobin et al.108 RRID:SCR_004463
HTSeq Putri et al.109 RRID:SCR_005514
Galaxy The Galaxy community110 RRID:SCR_006281

RESOURCES